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Abstract 
Oral oncolytics continue to come to market at an unprecedented pace. Traditionally, 
chemotherapy was delivered in the controlled environment of the infusion suite; however, 
with the increasing use of oral oncolytics, the burden of administration and monitoring 
has shifted to the patients and/or their caregiver. This paradigm shift, from intravenous 
chemotherapy to oral chemotherapy, has created new challenges in cancer care. Despite 
the seriousness of their diagnosis, oncology patients are not always adherent to these 
requirements. Oncology nurses have always taken the lead in patient education, yet that 
lead has mostly been in the context of intravenous chemotherapy. There is currently a 
lack of evidence to guide oncology nurses with their interactions with patients on oral 
chemotherapy. If patients are not adherent with their prescribed therapy, then progressive 
disease and premature death may be the outcome of their non-adherence. This project 
was a systematic review and synthesis of 51 articles on oral adherence and the subsequent 
development of a guideline based on the evidence that nurses can use to guide their 
interactions with patients on oral chemotherapy. The synthesis was divided into ways to 
measure adherence, factors contributing to non-adherence, and interventions to improve 
adherence. Knowing the factors contributing to non-adherence, how best to measure 
adherence, and the interventions to improve adherence can assist the nurse to plan 
individualized patient care. Adherence is critical for optimal patient outcomes and nurses 
play a key role in helping patients remain adherent. Education, monitoring, and ongoing 
support are necessary to help patients remain adherent and achieve optimal clinical 
outcomes. The scholarly product, a guideline on oral adherence, can be used by nurses to 
guide their interactions with adult patients on oral chemotherapy. 

  
 Patient Adherence to Oral Oncolytics  
by 
Holly SanSoucie 
 
 
 
MSN, Western Connecticut State University, 1998 
BSN, Excelsior College, 1994 
 
 
 
Project Submitted in Partial Fulfillment 
of the Requirements for the Degree of 
Doctor of Nursing Practice 
 
 
Walden University 
November 2013 
 
 
All rights reserved
INFORMATION TO ALL USERS
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a complete manuscript
and there are missing pages, these will be noted.  Also,  if material had to be removed, 
a note will indicate the deletion.
Microform Edition © ProQuest LLC.
All rights reserved. This work is protected against
unauthorized copying under Title 17, United States Code
ProQuest LLC.
789 East Eisenhower Parkway
P.O. Box 1346
Ann Arbor,  MI 48106 - 1346
UMI  3598866
Published by ProQuest LLC (2013).  Copyright in the Dissertation held by the Author.
UMI Number:  3598866
  
Acknowledgments 
 This academic journey could not have been accomplished without the support and 
encouragement of many. First and foremost, I would like to thank my committee chair, 
Dr. Andrea Jennings-Sanders for her guidance, scholarship, and encouragement. I would 
also like thank my committee members, Dr. Phyllis Morgan and Dr. Stoerm Anderson for 
their insightful comments and feedback on my work. I could not have accomplished this 
work without my preceptor, Dr. Margaret Irwin. Her guidance and expertise during my 
project allowed me to grow both professionally and personally. I greatly appreciate her 
contributions of time, ideas, and support. 
I thank my dearest friend, Allene, for her unwavering support. Working full-time 
and being a full-time student could not have been accomplished without the support and 
encouragement of my Director, Carol Bezick. They both believed in me when I started to 
doubt myself and I am deeply grateful for their support and encouragement. 
To my family whose love and support made this journey possible, my heartfelt 
thanks and gratitude. I dedicate this work to my son, BJ, who has always been my 
inspiration to reach for the stars. As you said, “make it happen”… and so I did! 
 
 
 i 
Table of Contents 
List of Tables ......................................................................................................................iv 
List of Figures .................................................................................................................... v 
Section 1: Nature of the Project .......................................................................................... 1 
Introduction ............................................................................................................. 1 
Problem Statement/Project Question ...................................................................... 2 
Purpose Statement and Project Objectives ............................................................. 4 
Significance to Practice........................................................................................... 4 
Evidence-based Significance of the Project ............................................................ 6 
Social Change in Practice ....................................................................................... 7 
Definitions of Terms ............................................................................................... 9 
Assumptions and Limitations ............................................................................... 10 
Section 2: Literature Review ............................................................................................ 12 
Specific Literature ................................................................................................. 12 
General Literature ................................................................................................. 13 
Causes of Non-Adherence .................................................................................... 13 
Adherence to Cancer Agents ................................................................................ 14 
Measuring Adherence ........................................................................................... 15 
Conceptual Model ................................................................................................. 17 
Section 3: Methodology .................................................................................................... 21 
Project Design ....................................................................................................... 21 
Data Collection ..................................................................................................... 23 
Evaluation Plan ..................................................................................................... 25 
 ii 
Summary ............................................................................................................... 26 
Section 4: Discussion and Implications ............................................................................ 27 
Project Summary and Evaluation Report .............................................................. 27 
Summary of Findings ............................................................................................ 28 
Measuring Adherence ........................................................................................... 29 
Factors Affecting Adherence ................................................................................ 30 
Interventions to Improve Adherence .................................................................... 31 
Discussion of Findings in the Context Of Literature and Frameworks ................ 34 
Implications........................................................................................................... 36 
Practice .................................................................................................................. 36 
Implications for Social Change in Practice ........................................................... 37 
Strengths ............................................................................................................... 40 
Limitations ............................................................................................................ 40 
Analysis of Self ..................................................................................................... 41 
Scholar .................................................................................................................. 41 
Practitioner ............................................................................................................ 41 
Project Developer.................................................................................................. 42 
Meaning for Future Project Development ............................................................ 42 
Summary and Conclusion ..................................................................................... 42 
Section 5: Scholarly Product ............................................................................................. 45 
Summary and Conclusions ................................................................................... 45 
Guideline on Oral Adherence ............................................................................... 47 
References ......................................................................................................................... 53 
 iii 
Appendix A: Conceptual Model of Project ...................................................................... 60 
Appendix B: Supporting Evidence for Guidelines on Oral Adherence ............................ 61 
Appendix C: ONS Putting Evidence into Practice Weight of Evidence Classification 
Schema .................................................................................................................. 90 
Curriculum Vitae .............................................................................................................. 95 
 
 
 iv 
List of Tables 
Table 1. Factors Contributing to Lack of Adherence …….……………………………...49  
Table 2. Recommendations on Intervention Categories to Improve Adherence ………...51
Table B1. Evidence Table for Factors Contributing to Lack of Adherence ……………..62 
Table B2. Evidence Table for Recommendations on Intervention Categories to Improve 
Adherence ………………………………………………………………………..76
 v 
List of Figures 
 Figure 1. Tally of articles included in review .................................................................. 29 
  
 
1 
 
Section 1: Nature of the Project 
Introduction 
 Oral oncolytics continue to come to market at an unprecedented pace with the recent 
approval of an increasing number of oral versus intravenous chemotherapy drugs. Michuad and 
Choi (2008) reported that 25% of all oncolytics in research and development are oral. This influx 
of oral agents into the oncology setting has brought to light a new and growing concern, that of 
non-adherence in the oncology patient. Although non-adherence to medication regimens, 
especially in the chronic disease setting, is not new, it has caught many in the oncology setting 
off guard. Healthcare Practitioners presume that oncology patients would be adherent just due to 
the severity of their disease, however this is not necessarily turning out to be the case. This shift 
in treatment from the controlled environment of the infusion suite where patients are in an 
environment monitored by nurses, to the patient’s home has created new challenges. 
 Patients and their caregivers are now responsible for adhering to complex dosing 
regimens, monitoring symptoms, management of side effects and toxicities, coordination of drug 
delivery, and dosing adjustments (as cited in Spoelstra et al., 2013, p. 19). Many oral oncolytics 
have a narrow therapeutic window and adherence is important in preventing disease progression 
and mortality. In a study by McCowan et al. (2008), the authors concluded that adherence to 
tamoxifen that is less than 80% has a negative effect on survival. Exploring adherence, including 
the ways in which it is measured, the factors contributing to non-adherence, and interventions 
demonstrated to improve adherence can provide future direction to developing efforts that assist 
patients to remain adherent and subsequently improve clinical outcomes. This project will 
culminate in a guideline based on the evidence to assist nurses with their interactions with adult 
patients on oral oncolytics. 
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Problem Statement/Project Question 
 The clinical practice problem is the lack of evidence to guide nurse’s practice on 
managing patients on oral oncolytics. The issue of non-adherence is multi-factorial and it appears 
that many of the contributing factors that have been documented in the chronic disease setting 
may be true for the oncology population. An important change in recent years related to cancer 
treatment has been the increased understanding of signaling pathways that regulate cellular 
activity thus allowing a cancer diagnosis to become a chronic disease for many. 
 Oral oncolytics provide patients with greater flexibility and convenience and less 
disruption of activities of daily living (Schneider, Hess, & Gosselin, 2011). In a study by Liu, 
Franssen, Fitch, and Warner (1997) of 103 patients, 89% reported a preference for oral 
chemotherapy. In a quantitative review of 50 years of research, the adherence rate was 24.5% (as 
cited in Spoelstra et al., 2013, p. 20). Reviews specific to oral oncolytics found adherence rates 
between 16-100%. More specifically, adherence for patients with a 28 day cycle was 88%, for 
patients with a 14 day on, 7 day off cycle was 36%, and 33% with a 7 day on, 7 day off cycle (as 
cited in Given, Spoelstra, & Grant, 2011, p. 98). Nilsson et al. (2006) concluded from their study 
that ambulatory patients who received anticancer drugs showed the same level of non-adherence 
as patients treated with other types of drugs. According to Spoelstra and Given (2011), there are 
few published studies that have focused on adherence to oral oncolytics. In a literature search by 
the same authors to identify studies that examined adherence to oral antineoplastics among 
cancer patients between 1975-2010, they found 30 adult studies (12 hormonal and 18 non-
hormonal). 
 The problem that I addressed in this project was the increasing use of oral oncolytics and 
the lack of evidence to guide nurses on how to best assist their patients to remain adherent. The 
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focus of my project was to perform a systematic review and synthesis of the literature around 
adherence to oral medications and develop a guideline for recommendations for practice. 
Considering until recent years most chemotherapy was administered in the controlled 
environment of the chemotherapy suite, oncology nurses have not had to deal with educating and 
monitoring patients on oral adherence. For this reason, they are not well versed in what 
interventions assist patients in being adherent. I focused my search into three separate areas or 
themes: scales used to measure adherence, factors contributing to non-adherence, and 
interventions to improve adherence. The subsequent synthesis of the literature around these areas 
will allow for development of a guideline that nurses can use with their patients on oral 
oncoloytics. The research questions were:  
1) What interventions have been shown to improve adherence in patients prescribed oral 
oncolytics,  
2) What are the factors that contribute to lack of patient adherence to oral medications, and  
3) How can adherence to oral therapy be assessed and evaluated? 
 Many interventions have been studied in the chronic disease setting such as by Ruddy, 
Mayer, and Partridge (2009) looking at patient diaries, pill counts, serum or urine drug or 
metabolite levels, and the medication event monitoring system (MEMS). Evidence retrieved in 
this project was critiqued to determine the strength and quality of the evidence and if the 
outcomes can be applied in the oncology setting. Understanding the reasons why patients do not 
take their oral oncolytics as prescribed is important to development of potential interventions to 
improve adherence. In this literature review, I also considered evidence regarding contributing 
factors to non-adherence in order to synthesize this evidence as well. 
 Lastly, I included a review of instruments that are typically used to measure and monitor 
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adherence. This provided the evidence on what measurement scales have been used successfully, 
and that could be recommended for future use. Assessment and monitoring patient adherence is 
key toward effective management of therapy. My review of measurement and assessment 
methods enabled me to synthesize the evidence in this area. 
Purpose Statement and Project Objectives 
 The purpose of this project was to synthesize the literature on adherence to oral drugs, 
specifically oral oncolytics, in adult cancer patients in order to provide recommendations for 
practice. The objectives for this project were first, to perform a systematic review of the 
literature around adherence identifying causes, measurement tools, and interventions. My search 
included both oncology and chronic disease literature dating from 1997-2013. Second, was a 
critique of the literature. Third, was to create a synthesis of the evidence related to measuring 
adherence, the contributing factors to non-adherence, and the interventions shown to improve 
adherence and to develop a guideline for practice recommendations for nurses to use with their 
patients on oral chemotherapy. This synthesis will be disseminated to the Oncology Nursing 
Society (ONS) as they form a project team to determine if there is enough evidence to develop 
an evidence-based resource on oral adherence for publication. 
Significance to Practice 
 Oncology nurses have historically taken the lead in patient teaching for chemotherapy. 
However, that chemotherapy was administered in the controlled environment of the office/clinic, 
by the term coined in most practices as chemo nurses. When a patient receives a prescription for 
an oral oncolytic, the patient often does not see a nurse. This is in large part due to the workflow 
of the office. As this issue continues to come to light, clinics will need to rethink how they 
manage patients on oral oncolytics. For those practices that have a system in place to teach these 
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patients, that teaching is new in oncology since previous teaching revolved around intravenous 
chemotherapy. Nurses are unfamiliar with what interventions have been shown to improve 
adherence. Most of the literature is in the chronic disease setting as determined in my initial 
literature search and was the foundation of the literature reviewed. Not much literature exists 
regarding adherence in the oncology patient and it will likely be several more years before that 
literature becomes more readily available. Side effects of oral oncolytics may be different from 
oncolytics delivered via the intravenous route but they have the same potential for severity, 
making patient education and monitoring equally important for both (Wood, 2012). 
 With the continued approval of oral oncolytics expected, patient education and 
monitoring of patients on oral oncolytics will continue to increase in importance. Low treatment 
adherence, even when patients are taking life-saving therapy, demonstrates the need for better 
management and monitoring of patients on oral oncolytics. Poor adherence can severely impede 
the efficacy of an oral oncolytic and if a prescriber is not aware that a patient is non-adherent, 
disease progression may be attributed to lack of drug efficacy and may result in a regimen 
change (Ruddy, Mayer, & Partridge, 2009). An understanding of both the barriers to adherence 
and the strategies that can be used to effectively manage patients can equip oncology nurses with 
the tools needed to improve adherence (Wood, 2012). This project produced a guideline on oral 
adherence based on the evidence, which will assist nurses in their teaching of patients prescribed 
oral oncolytics. If, in fact, nurses and clinical sites use the guideline and incorporate it into 
clinical practice, it will have the potential to change the standard of care around how patients on 
oral oncolytics are educated and monitored.  
 Possibly most important is that nurses have always taken the lead on patient education. 
Barton (2011) posited that one of the most important aspects of helping patients adhere to oral 
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treatment is to educate them about the role of therapy in their disease. Providing nurses the 
evidence on factors contributing to non-adherence can assist nurses in doing this consistent with 
the evidence. A better understanding of the reasons for non-adherence can help direct the 
research to interventions to improve adherence. This project will contribute to the ONS’ Putting 
Evidence into Practice (PEP) project team’s work. They will examine the evidence on a larger 
scale and a final product will be published on the topic. It is too early to know exactly what that 
final product will be as it is possible there may not be enough evidence to produce an evidence-
based resource on oral adherence. If a PEP resource cannot be developed due to the lack of 
evidence then it is anticipated a whitepaper or article around the state of the knowledge will be 
published. However, whatever the final product is it will contribute to the body of knowledge for 
oncology nurses caring for patients on oral oncolytics by providing them with what is currently 
known, based on the evidence, on the topic. 
Evidence-based Significance of the Project 
 It is well established that our nursing practice should be based on the evidence 
(Newhouse, Dearholt, Poe, Pugh, & White, 2007). Nurses need to know what the best evidence 
is around oral adherence. The significance of this project is the review and synthesis of the 
literature around oral adherence where I provide a summary of the best, current evidence and 
make it available to nurses. By understanding the state of knowledge around this topic it has 
allowed me to identify areas for research, identify gaps in the research, and identify the best tools 
related to measuring and assessment of adherence if they exist. Having a better understanding of 
the current literature can also be used to design future interventions to improve adherence based 
on what has already been researched. Nurses need to know what interventions work based on the 
evidence so they can employ them in their practice of teaching patients about adherence.  
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Social Change in Practice 
 Non-adherence has been associated with the increased consumption of healthcare 
resources resulting in higher hospitalization rates and longer stays. It is estimated that non-
adherence costs the United States healthcare system an estimated annual $100 billion to $300 
billion while another estimate states that the hospital costs due to non-adherence amount to an 
annual $8.5 billion price tag. Doggrell (2010) indicated that medication wastage costs the United 
States over $1 billion per year. If a patient is non-adherent while participating in a clinical trial, 
inaccurate conclusions and flawed dosing recommendations may result (Soper, Hubbard, & 
Foster, 2009). Improving adherence can recognize a gain in health outcomes and a decrease in 
wasted prescriptions filled but not used. Improved adherence confers economic benefits by 
reducing the use of health services needed in disease exacerbation, crisis, or relapse. According 
to Sabate and the World Health Organization (WHO) (2003), the indirect savings are recognized 
in the preservation of quality of life and the social and vocational roles of patients (Sabate & 
WHO, 2003). They also conclude strong evidence suggests that self-management programs in 
patients with chronic diseases improves health status and reduces utilization and costs. 
 Additionally, when self-management and adherence programs are combined with regular 
treatment and disease specific education significant improvements in health promoting 
behaviors, cognitive symptom management, communication and disability management have 
been recognized. The number of patients being hospitalized, days in the hospital, and the number 
of outpatient visits has also been reduced (Sabate & WHO, 2003). Ultimately improving 
adherence through patient education and monitoring should decrease the healthcare costs 
associated with non-adherence and improve patient’s quality of life. According to Sabate and 
WHO (2003), if we are able to increase the effectiveness of adherence interventions this may 
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have a far greater impact on the health of the population than any improvement in specific 
medical treatments. 
From the patient’s perspective, a patient’s inability to adhere to their prescribed regimen 
can negatively affect clinical benefit and result in treatment resistance, disease progression, and 
death (Oncology Nursing Society [ONS], n.d.a.). Adhering to an oral cancer therapy can be a 
challenging commitment for patients and their caregivers and oral cancer therapies are most 
effective when patient adherence is optimized (ONS, n.d.b). The problem of non-adherence to 
prescribed therapies is widespread and impacts all socioeconomic classes and disease states. In 
the United States, 50-70% of patients do not take their medication as prescribed, 60% of patients 
cannot actually identify their own meds, and 30-50% ignore, or otherwise compromise, 
prescription related instructions (Soper, Hubbard, & Foster, 2009). In a study by Esposito, 
Bagchi, Verdier, Bencio, and Kim (2009), where the authors examined medication adherence 
and chronic heart failure, hospital and emergency department outcomes were lower for adherent 
patients compared with non-adherent patients. Additionally, adherent patients were less likely to 
have a hospitalization, had fewer hospitalizations per patient, were less likely to have an 
emergency room visit, and had fewer emergency room visits per patient. Non-adherence 
regardless if it is in the chronic disease setting or in the oncology setting has negative clinical 
outcomes for patients and causes them to increase utilization of health care services. 
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Definitions of Terms 
 Adherence to long-term therapy: “The extent to which a person’s behavior-taking medication, 
following a diet, and/or executing lifestyle changes, corresponds with agreed upon 
recommendations from a healthcare provider” (Sabate, & WHO, 2003, p. 17). 
AGREE II Instrument: The Appraisal of Guidelines for Research and Evaluation (AGREE) 
instrument evaluates the process of practice guideline development and the quality of reporting; 
it is valid and reliable and comprises 23 items organized into six quality domains (Brouwers, M., 
Kho, M. E., Browman, G. P., Burgers, J. S. Cluzeau, F. Feder, G., … Zitzelsberger, L. 2010). 
Cochrane Reviews: Systematic review of primary research in human health care and health 
policy, and are internationally recognized as the highest standard in evidence-based health care 
(The Cochrane Collaboration, 2012). 
Intervention: The act of intervening, interfering, or interceding with the intent of modifying the 
outcomes. In medicine, an intervention is usually undertaken to help treat or cure a condition 
(Medicine Net, 2012). 
Oncolytic: Pertaining to the destruction of tumor cells (The Free Dictionary, 2012a). 
Oral Medication: The administration of a tablet, a capsule, an elixir, or a solution or other liquid 
form of medication by mouth (The Free Dictionary, 2012b). 
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Assumptions and Limitations 
  Oncology nurses typically take the lead in educating patients about intravenous 
chemotherapy. Most office practices workflow is set up to allow this to take place. There is a 
clear dichotomy in how patients are educated for intravenous chemotherapy versus oral 
chemotherapy. Most of the education that takes place for patients receiving intravenous 
chemotherapy is done by chemotherapy nurses, whereas, patients receiving a prescription for an 
oral oncolytic generally never see a chemotherapy nurse simply due to the flow of the office. 
Because this is a rising issue in oncology, there is limited data around adherence in the literature 
specific to the oncology patient. Non-adherence is multifactorial and it appears that some of the 
causes that contribute to non-adherence in the chronic disease setting are also causes in the 
oncology setting.  
 The first limitation is the limited data around oral adherence in the oncology patient. 
Most of the literature is in the chronic disease setting, which was reviewed for this project. The 
second limitation is that there is plethora of literature around adherence in the chronic disease 
setting and due to the time constraints of this project, all of the literature was not able to be 
included in this review. The final limitation is that the synthesis of the evidence and 
dissemination of it does not guarantee that nurses and/or clinical sites will use the information to 
guide their nursing interactions with patients on oral oncolytics.  
Summary 
Nurses can have a significant influence on patient adherence by providing thorough and 
timely patient and family education and by monitoring and managing side effects (Winkeljohn, 
2010). Nurses can take the lead in developing programs, measurement tools, and interventions 
that can improve adherence and patient outcomes. With this project it was my goal to synthesize 
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the literature and provide evidence-based information in order to build a guideline on oral 
adherence. It was also my goal to assist nurses with implementing this guideline. The upcoming 
sections will examine the current literature on the topic of adherence, the conceptual framework 
and evaluation method of the project and the synthesis of the literature examined to develop the 
guideline on oral oncolytics. 
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Section 2: Literature Review 
Specific Literature 
 Adherence to long-term therapy is defined as “the extent to which a person’s behavior-
taking medication, following a diet, and/or executing lifestyle changes corresponds with agreed 
upon recommendations from a healthcare provider” (Sabate & WHO, 2003, p. 17). The literature 
is sparse around adherence specific to the oncology population. This is likely in part because 
there has been a significant span of time between the first few early oral oncolytics and the 
recent approval of many oral oncolytics over the last several years.  
According to Michaud and Choi (2008) with 25% of current oncolytics in research and 
development being oral this issue will only increase in prevalence. The rates of non-adherence 
vary in the literature but the first cancer observation studies were done with hormonal therapy in 
breast cancer and reported adherence rates from 20%-100% (Regnier, Poirson, Nourissat, 
Jacquin, Guastalla, & Chauvin, 2010). In the 1990’s researchers discovered signaling pathways 
that regulate cellular activities, and found alterations in these pathways in cancer cells and this 
science has lead to the development of targeted therapies, a large class of oral oncolytics 
(Foulon, Schoffski, & Walter, 2011).  
For decades, most chemotherapy was administered intravenously and services were 
organized based on this type. The shift to treating cancer with oral agents has created a new 
paradigm, challenging traditional attitudes toward cancer care and requiring new concepts of 
organization in oncology care and services (Foulon et al., 2011). Oral therapy is often preferred 
by patients over intravenous therapy for several reasons: (a) oral therapy can promote a feeling 
of control; (b) decrease interference with work and social activities; (c) eliminate travel time to 
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an infusion clinic; and (d) eliminate the discomfort and need for a peripheral intravenous line (as 
cited in Wood, 2012, p. 432).  
Additionally, patients are willing to accept oral therapy as long as side effects are not 
worse than those expected with intravenous treatment and the greater sense of control over their 
therapy is viewed as a benefit of oral versus intravenous (Foulon et al., 2011). For patients on 
oral therapy, the burden of treatment administration is shifted to the patient, causing greater 
difficulties in assessing treatment adherence and monitoring of side effects than with patients 
receiving intravenous treatment (Wood, 2012). Given that efficacy is not compromised, most 
patients prefer oral to intravenous. According to the National Comprehensive Cancer Network, a 
key factor in assessing appropriateness for prescribing oral anti-cancer treatment is adherence (as 
cited in Foulon, et al., 2011, p. 87).  
  
General Literature 
Causes of Non-Adherence 
 The literature search revealed the causes for non-adherence to be multi-factorial and 
include lack of understanding proper treatment administration, complex dosing regimens, 
interaction with other medications, timing of doses in relation to food intake, cost, and side 
effects (Wood, 2012). Atkins and Fallowfield (2006) posited that adherence is not necessarily 
related to socio-demographic factors such as age, sex, level of education, or race but that patients 
are less likely to adhere to those therapies that have adverse side-effects, are complex, and/or last 
longer. They go on to cite Elwyn and colleagues who suggest that intentional non-adherence is 
the result of three factors: (a) a lack of information about the advantages and disadvantages of 
the treatment; (b) when the benefits of the treatment are not obvious; and (c) the psychological 
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adaptation required to see oneself in need of treatment. Adherence is less likely where the 
benefits of the drug are not immediately obvious. This is significant for women with a diagnosis 
of breast cancer on hormonal therapy for 5 years, which does not offer a guarantee of recurrence-
free survival while producing side effects.  
 Another issue demonstrated in an international survey conducted by Kav et al., (2008) is 
that 47% of nurses reported they felt inadequately educated on oral chemotherapy drugs (Kav et 
al., 2008). Citing this study in his own research, Wood posited that patient education can 
promote a better understanding of the patient treatment regimen and highlight the importance of 
adherence (Wood 2012). However, Wood concludes that it appears that before nurses can 
educate patients they themselves need education on the drugs. This presents another issue that is 
outside the scope of this project. According to Hede (2009), there is no procedure, in any office, 
to effectively prescribe and manage oral oncolytics. 
Adherence to Cancer Agents 
In a study performed by Atkins and Fallowfield (2006), the authors concluded that 55% 
of woman currently receiving medication for their breast cancer did not adhere to the treatment 
regimen. In addition, they found that 54% of women prescribed tamoxifen and 61% prescribed 
an aromatase inhibitor reported non-adherence. In a study completed by Barron, Connolly, 
Bennett et al., (cited by Schneider, Hess, and Gosselin (2011)), researchers found that within 1 
year and within 3.5 years of starting tamoxifen, 22.1% and 35.2% of patients had discontinued 
therapy. Partridge, Philip, Winer, and Avorn (2003) reported adherence rates dropped from 87% 
in the first year to 50% by year four for breast cancer patients being treated with tamoxifen for 
five years. 
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As demonstrated by these data, much of the research related to the oncology patient has 
been in the hormonal agents as this was the largest group of oral agents used in cancer treatment 
until the recent increase in targeted oral anti neoplastic agents. In a study specific to oral 
oncolytics, Lebovits, Strain, Schleifer, Tanaka, Bhardway, and Masse (1990) reported a 43% rate 
of non-adherence for breast cancer patients taking oral cyclophosphamide and/or prednisone. 
Lastly, in a study by Levine et al. (1987), serum drug metabolites demonstrated that only 26.8% 
of patients had adequate levels of prednisone and 16.8% had adequate levels of allopurinol while 
the patient self-reports of adherence were greatly over-estimated. The adherence rates in the 
aforementioned studies indicate that there is significant room for improving adherence to oral 
cancer therapy. 
Measuring Adherence 
 A current challenge in monitoring adherence is that no gold standard currently exists. 
Little research has been done to measure adherence specific to the oncology patient and the 
definition of adherence varies between studies. Studies have shown that adherence measures 
have limitations, which then beckons the question of how best to measure drug-taking behavior 
(Spoelstra & Given, 2011). Self-reporting has traditionally been used to measure adherence but 
this method is fraught with inaccuracies as patients tend to over-report their drug taking (Wood, 
2012). Additionally, medication possession ratio as a measurement scale is used frequently in 
studies to examine adherence however, it is most commonly seen in the chronic disease 
literature. 
It is evident that more current research needs to be conducted now that there are many 
new oral oncolytics on the market. Researchers and practitioners need to determine if the reasons 
for non-adherence in the oncology setting are similar to those in the chronic disease setting and 
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what interventions oncology patients find most helpful. Ruddy, Mayer, and Partridge (2011) 
suggested that studies need to be done to investigate which diseases and which therapies are 
significantly impaired by missed doses so that interventions to optimize adherence can be 
targeted to the patients who are most in need. 
 There is a plethora of literature around adherence in the chronic disease setting. A 
MEDLINE and CINAHL search that I conducted returned over 7,000 articles. People are living 
longer and longer life is accompanied by an increase in chronic conditions (Williams, Manias, & 
Walker, 2008). Prescribing medications and patient’s adherence is key to managing these chronic 
conditions. The effectiveness of medications and their long-term benefits depend on patient 
adherence to their prescribed regimen (Williams et al., 2008). In patients with diabetes, up to 
37% have discontinued oral hypoglycemic drugs within one year of initiating treatment (Farmer 
et al., 2012). In Human Immunodeficiency Virus (HIV) patients, where adherence rates need to 
remain >90% to suppress the virus, adherence rates are reported to be 75-80% with rates 
declining even further as the length of time on therapy increases (Fisher et al., 2011). DiMatteo 
(2004) performed a quantitative review of 50 years of research and reported that medication 
adherence is approximately 24.5%. According to Sabate and WHO (2003, p. 11), there is strong 
evidence that many patients with chronic illness have difficulty adhering to their recommended 
regimens and that 50% of patients who have chronic diseases do not take their medicines. 
 Poor adherence is the primary reason for sub-optimal clinical benefit and causes medical 
and psychosocial complications of disease, reduces patient’s quality of life, and wastes 
healthcare resources. These direct consequences impair the ability of the healthcare systems 
around the world to achieve population health goals. The report goes on to say “the conclusions 
of research in this area are unequivocal-adherence problems are observed in all situations where 
17 
 
the self administration of treatment is required, regardless of type of disease, disease severity, 
and accessibility to health resources” (p. 11). 
 According to Williams, Manias, and Walker (2008) 30-60% of people are non-adherent 
to prescribed medications and this figure rises when multiple chronic conditions are involved. 
Adherence can slow disease progression and reduce health care costs. In a systematic review in 
people with multiple chronic illnesses, adherence was not routinely defined and was measured 
using different self-report tools and estimates of adherence. In this same analysis, investigators in 
prospective intervention studies recommend combinations of tailored educational, behavioral, 
and affective strategies that include family support and regular patient contact. Williams et al. 
conclude that healthcare systems that recognize, value, and fund initiatives, which support 
consumers to take medications as prescribed are essential (Williams et al., 2008). Additionally, 
they posit that nurses need to know how best to help and advocate for patients based on the 
evidence.  
Conceptual Model 
 Evidence-based practice is a problem-solving approach to clinical decision making that 
integrates the best available scientific evidence with the best available experiential evidence 
(Newhouse et al., 2007). Nurses using evidence-based practice as a foundation for their practice 
are able to enlighten practice and add value to the patient experience. Nursing practice based on 
the evidence is critical to realizing healthcare improvements and cost savings (Newhouse et al., 
2007). According to Newhouse et al., (2007), the key assumptions of evidence-based nursing 
practice include: (a) nursing is both a science and applied profession, (b) knowledge is important 
to professional practice and the limits to knowledge must be identified, (c) not all evidence is 
created equal, and there is a need to use the best available evidence, and (d) evidence-based 
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practice contributes to improved outcomes.  
The evidence-based practice model that I used to guide my DNP project was the Johns 
Hopkins Nursing Evidence-Based Practice Model (JHNEBP). I selected this model because of its 
simplicity and ease of applying it to the research process and more specifically to my project. 
The model can be described as PET: practice question, evidence, and translation. The first phase 
is the development of an answerable, evidence-based question. The second phase is the search 
for, and appraisal of, the best available evidence. The last phase, translation, is determining if the 
changes to practice are feasible. 
Developing questions allows researchers to determine what information to seek and the 
direction in which to search and the question should be clear, accurate, precise, and relevant 
(Newhouse et al., 2007). Practice settings provide the source of most evidence-based practice 
questions. Practice issues for inquiry can come from a multitude of sources including safety/risk 
management concerns, unsatisfactory patient outcomes, wide variations in practice, financial or 
cost concerns, differences between hospital and community practice, clinical practice issues of 
concern, procedures or processes that waste time, or practices with no scientific basis (Newhouse 
et al., 2007). My practice question arose from a clinical practice issue of concern, that being lack 
of patient education and monitoring of patients prescribed oral oncolytics and its contribution to 
non-adherence.  
The second phase requires proficiency in seeking information, analyzing, synthesizing, 
interpreting, and drawing conclusions from available information. Rating scales are used to 
provide a structured way to enhance the critical thinking skills of the reviewer by applying 
standardized levels to evidence to differentiate among evidence of varying strengths and quality 
(Newhouse et al., 2007). Once the literature has been reviewed and synthesized, then the 
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determination needs to be if it is appropriate to move to the last step in the process, which is 
translation. The first step in translation is asking: Should practitioners implement this practice 
recommendation? The steps involved in translation involve assessing the feasibility and 
appropriateness of the recommendation, creating an action plan, pilot on a small scale, evaluate 
the change, report it to the appropriate stakeholders, foster support, wider implementation plan, 
and communicate the findings (Newhouse et al., 2007). 
The model includes a set of tools for use at each of the phases including an evidence 
appraisal guideline, a review tool for scientific evidence, and a summary of evidence review and 
recommendations (White & Dudley-Brown, 2012). Specifically, the JHNEBP Research 
Evidence Appraisal form has areas addressing the strength of study design, results, and 
conclusions. These components are included in the ONS’s form that I will use for documentation 
of my article critiques since it is my hope that this work will continue on with ONS and 
culminate in a formal evidence-based guideline published by them. Having my critiques on their 
form will facilitate this ongoing process. I believe this model fits nicely with my systematic 
review around adherence to oral oncolytics and developing an evidence-based resource for 
oncology nurses on the topic. See Appendix A for the schematic of the conceptual model for this 
project. 
There are several variables that could be the result of this project. The first variable is the 
literature may demonstrate that there is not enough evidence around interventions that have been 
shown to improve adherence. It is possible that there is not enough literature around 
interventions to improve adherence in the oncology setting but it is possible that the chronic 
setting literature may not produce enough data to support interventions that improve adherence. 
The second variable is there are proven interventions in the chronic disease setting but they are 
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not applicable in the oncology setting. For example, decreasing pill burden improves adherence 
but this may not be possible with oral oncolytics in the current marketplace but could prove to be 
valuable insight for drug manufacturers. The final outcome variable is that at least some of the 
interventions that have been shown to improve adherence in the chronic disease setting could be 
applicable in the oncology setting with oral oncolytics, and I will present this information in my 
synthesis of the literature. In the upcoming section, the project design, data collection, and 
project evaluation will be discussed. 
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Section 3: Methodology 
Project Design 
 This project was a systematic review and synthesis of the literature. The purpose of a 
systematic review is to synthesize the best available research on a specific question. In my 
review, I used a transparent procedure to find, evaluate, and synthesize the results of the existing 
research. A systematic review must have clear inclusion/exclusion criteria, an explicit search 
strategy, systematic coding and analysis of included studies and a meta-analysis (The Campbell 
Collaboration, n.d.).  
 Cochrane Reviews are systematic reviews of primary research in health care. These 
reviews are internationally recognized as the highest standard in evidence-based healthcare. Each 
systematic review addresses a clearly formulated question. All of the existing, primary research 
that meets certain criteria is searched for, collated, and assessed using stringent guidelines to 
establish whether or not there is conclusive evidence about a specific treatment (The Cochrane 
Collection, 2012). Often, an individual or company might actively seek to discuss only the 
research that supports their opinions or commercial interests. The Cochrane Review avoids this 
by using predefined, rigorous, and explicit methodology. 
 The Cochrane Review is a scientific investigation in itself, with a preplanned methods 
section and an assembly of original studies, which are comprised of mostly randomized clinical 
trials and the results of these multiple primary investigations are synthesized by using strategies 
that limit bias and random error. These strategies include a comprehensive search of all relevant 
studies and the use of explicit, reproducible criteria in the studies selected for review. The 
primary research designs and study characteristics are appraised, data synthesized, and results 
interpreted (The Cochrane Collection, 2012).  
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 I selected the systematic review because it allows for review of the evidence around oral 
adherence and more specifically oral oncolytics. It would help me to identify gaps in the 
research, and the synthesis would provide nurses with the evidence of what interventions have 
been shown to improve adherence. As previously stated, most oncology nurses have been 
involved in the teaching, administration, and monitoring of intravenous chemotherapy in the 
infusion suite. This is a new area of clinical concern in the oncology setting and, in performing 
the systematic review I will provide nurses with the evidence to guide their practice.  
 The literature on oral adherence, specific to the oncology patient, is sparse but growing as 
the topic has been in the limelight for the past several years. Most of the literature on adherence 
to oral medications is in the chronic disease setting and because there may be valuable 
information around causes, scales used to measure adherence, and successful interventions my 
review included this literature as well. I expected that most of the literature that I reviewed 
would be of a mixed method approach and that turned out to be true. It combined quantitative 
data around adherence rates with qualitative data around understanding the causes of non-
adherence and what interventions patients find useful. According to Terry (2012, p. 13), the 
practitioner who conducts a systematic review is able to make an objective assessment of the 
available evidence, specifically of the outcomes of particular interventions that could be 
implemented and that evidence will be located, evaluated, and consolidated into a comprehensive 
and unbiased summary. This is the foundation for this project.  
 I searched the literature using MEDLINE, PubMed, CINAHL, and PsycINFO. 
Additionally, reference lists of papers that were eligible for inclusion in the systematic review 
were scanned for additional citations. The literature search of the electronic databases combined 
the following terms: medication adherence and oncology and/or cancer and/or neoplasm and/or 
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oral and/or chronic disease. The search included the following designs: systematic reviews, 
meta-analysis, randomized controlled trials, and non-randomized comparative cohort studies. I 
selected articles for inclusion in the evidence series if the authors reported data on measuring 
adherence, factors contributing to non-adherence, and interventions to improve adherence. Case 
reports, letters, and editorials were not considered for inclusion. Additionally, articles that 
included pediatrics, depression, cognitive disorders, psychiatric disorders, pregnancy, substance 
abuse, or measured adherence in clinical trials were excluded. 
Data Collection 
 This project was a systematic review of the literature around adherence, including in both 
the oncology and chronic disease populations. I reviewed 119 articles that were the basis for the 
review and synthesis. The articles that I included were on adherence to oral medications 
specifically focusing on measurement scales, factors contributing to non-adherence and 
interventions to improve adherence. My inclusion/exclusion criteria and Medical Subject 
Headings (MeSH) terms were established. Inclusion criteria included: medication adherence, 
medication compliance, causes/factors of non-adherence, measurement scales of adherence, 
interventions for adherence, oral medication, peer reviewed, 1997-2013, adult, and English. The 
exclusion criteria included: pediatrics, depression, cognitive disorders, psychiatric disorders, 
pregnancy, and substance abuse. The MeSH terms were: medication adherence, medication 
compliance, oncology and/or cancer and/or chronic disease and/or oral. 
 Data from the literature was collected via a standard form that the ONS currently uses for 
their review of the literature. Since this project will be used in the consideration of ongoing 
development of the topic by ONS, having the reviews on their form will more easily allow for 
the work to continue if they deem appropriate. The form titled, ONS PEP Research Summary 
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Form-July 2012 Version includes the following sections: (a) study reference information, (b) 
study purpose, (c) intervention description, (d) sample characteristics, (e) setting, (f) phase of 
care and clinical applications, (g) study design, (h) measurement/instruments, (i) results, (j) 
conclusions, (k) limitations, and (l) nursing implications. 
 I sorted the data for contributing factors of non-adherence, measurement scales, and 
interventions. Ultimately the data was reviewed, summarized, and synthesized. I then organized 
the synthesized data in an excel spreadsheet for ease of reading and identifying trends. This also 
followed the format ONS uses for its PEP resources. Additionally, each article that I included 
was graded based on the JHNBEP model for strength and quality of the evidence. 
 An Institutional Review Board (IRB) is a committee whose primary responsibility is to 
protect the rights and welfare of human research subjects as it reviews research proposals to 
ensure risks have been minimized and the potential for benefit has been maximized for the 
human subjects participating in the research. Participation in research is voluntary and requires 
legally effective informed consent. The IRB is required by federal and state laws and applies 
additional safeguards to vulnerable populations participating in research which includes children, 
prisoners, pregnant women, fetuses, and physically, mentally, economically, or educationally 
disadvantaged persons (The Ohio State University, 2013). 
 The IRB at Walden University is responsible for ensuring that Walden University 
research complies with the university’s ethical standards as well as United States federal 
regulations. IRB applications are required by all students and faculty members conducting 
research projects involving collection or analysis of data (Walden University, n.d.). The IRB 
approval for this project is 05-06-13-0327445. 
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Evaluation Plan 
 I evaluated the final outcome of this project, a guideline on oral adherence, in a manner 
similar to the evaluation of published guidelines. Additionally, in the case of this systematic 
review and synthesis of the literature, evaluation should determine if it was done in a manner 
consistent with evaluating this type of work. This project was evaluated by The Appraisal of 
Guidelines for Research and Evaluation Instrument (AGREE). The AGREE Instrument was 
published in 2003 by a group of international guideline developers and researchers called the 
Agree Collaboration. The original AGREE Instrument was a 23-item tool comprising six quality 
domains. It was developed to address the issue of variability in guideline quality and the tool 
assesses the methodological rigour and transparency in which a guideline is developed. The 
original AGREE Instrument has been refined and the purpose of the AGREE II Instrument is to 
provide a framework to: (a) assess the quality of the guidelines, (b) provide a methodological 
strategy for the development of guidelines, and (c) inform what information and how information 
ought to be reported in guidelines. The AGREE II Instrument is also a 23-item tool organized 
into six domains: (a) scope and purpose, (b) stakeholder involvement, (c) rigour of development, 
(d) clarity of presentation, (e) applicability, and (f) editorial independence. The instrument is 
generic and can be applied to guidelines in any disease area targeting any steps in the health care 
continuum, including those for health promotion, public health, screening, diagnosis, treatment, 
or interventions (Brouwers et al., 2010).  
 The AGREE II Instrument is more comprehensive than what is required for evaluation of 
this project and was not used in its totality, especially given the fact that my final outcome will 
not be a true guideline. Out of the aforementioned six domains, the sections that I utilized to 
review my work were domain number three, rigour of development and domain number four, 
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clarity of presentation. 
 The long-term effects of my evaluation plan included disseminating the information to 
the ONS PEP project team on oral adherence and to my local ONS chapter. This project will 
provide valuable information as we continue to evaluate what the most helpful information is to 
educate oncology nurses on improving oral adherence based on the evidence. Additionally, I 
planned to continue to participate in the oral adherence project team now that ONS has decided 
to move forward with developing the topic. The short-term effects were to provide updates on 
the literature review as I progressed through it to ONS.  Evaluating the intermediate health 
outcomes as a result of implementation of my project are outside the scope of it. It will be up to 
the nurses and/or clinical sites to use the information and make practice changes according to the 
evidence that my resource provides. 
Summary 
 My approach with this DNP project was similar to the approach used in the Cochrane 
Reviews. I performed a systematic review of the literature and synthesized it to develop a 
guideline around adherence to oral therapies and more specifically oral oncolytics. When  
completed, my project resulted in a guideline based on the evidence that guides nursing 
interactions on adherence in the oncology patient prescribed oral oncolytics. If nurses can be 
provided with interventions that have been shown to improve adherence they can and should 
focus their teaching based on the evidence and those interventions that can improve adherence. 
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Section 4: Discussion and Implications 
Project Summary and Evaluation Report 
 The purpose of this project was to synthesize the literature on adherence to oral drugs, 
specifically oral oncolytics, in adult cancer patients in order to provide recommendations for 
practice. The end product of this systematic review and synthesis of the literature is a Guideline 
on Oral Adherence, which I present in Section 5. The supporting evidence that I used to make 
the recommendations and develop the guideline is included in Appendix B. The guideline 
followed the format of the Cochrane Review, and includes a background, objective, search 
strategy, selection criteria, data collection and analysis, main results, and author’s conclusion. I 
evaluated the project using the AGREE II tool. 
 As I described in Section 3, this tool was intended to evaluate published guidelines to 
address the issue of variability in guideline quality. It is a tool that assesses the methodological 
rigor and transparency in which the guideline is addressed (Brouwers et al., 2010). The guideline 
developed for this project is not a guideline in the truest sense of the word and therefore portions 
of the AGREE II tool are not applicable for evaluating this guideline. For example, stakeholder 
involvement, applicability which includes monitoring and/or auditing criteria, and editorial 
independence do not apply to this project. Domains Three and Four will be used to evaluate the 
guideline. 
 Domain Three of the AGREE tool evaluates the rigor of development. It determines if: 
(a) systematic methods were used to search for the evidence, (b) the criteria for selecting the 
evidence are clearly described, (c) the strengths and limitation of the body of evidence have been 
considered in formulating the evidence, (d) the methods for formulating the recommendations 
are clearly described, (e) the health benefits, side effects, and risks have been considered in 
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formulating the recommendations, (f) there is an explicit link between the recommendations and 
the supporting evidence, (g) the guideline has been externally reviewed by experts prior to its 
publication, and (h) a procedure for updating the guidelines is provided. This guideline met 
criteria for items one to six and can be evidenced by viewing the guideline. Criteria seven and 
eight are not applicable to this guideline.  
 Domain Four evaluates the guideline for clarity of presentation: (a) is the 
recommendations are specific and unambiguous, (b) the different options for management of the 
condition or health issue are clearly presented, and (c) key recommendations are easily 
identifiable. This guideline meets the first criteria; the recommendations are specific regarding 
consideration for use. The recommendations are laid out in a table format according to the 
category of intervention and the recommendations for use in practice in one the six categories in 
the ONS classification schema. The second criterion does not apply to this guideline. The third 
criteria of easily identifiable recommendations is met and as stated previously the 
recommendations are straightforward and laid out in a table format.  
 Overall, this guideline met its objective. The guideline is the outcome of a systematic 
review and synthesis of the literature on oral adherence. However, the limitation it possesses is 
not all the literature could be included due to the vast amount of research on the topic and this 
author performing the review and synthesis single handedly. 
Summary of Findings 
Following my initial search, I located 142 relevant abstracts. Research and reviews 
reporting on measuring adherence, factors contributing to non-adherence, and interventions to 
improve adherence were included in the relevant abstracts. After review of the abstracts and 
articles, I selected 119 for this review. Ultimately, I excluded 41 of the 119 as they were on 
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measuring adherence or factors contributing to non-adherence and these two topic areas were 
saturated with the reviews already completed. It was deemed that there would be no new and/or 
additional information that could be gleaned from continuing review in these two areas. Upon 
further review, 27 articles did not meet the inclusion criteria. The final outcome was the 51 
articles that I included in this review. Of the 51, 14 were cancer related and 37 were related to 
chronic disease (see Figure 1). The most common chronic diseases included cardiovascular, 
diabetes, and HIV. 
  
Figure 1. Tally of articles included in review. 
Measuring Adherence 
My synthesis of the data on methods used to measure adherence showed that the 
Medication Possession Ration (MPR) and the Morisky Medication Adherence Scale were the 
two most common methods used to measure adherence. The MPR is defined by the number of 
doses dispensed in relation to a dispensing period (Netelenbos, J., Geusens, P., Ypma, G., & 
Bujis, S., 2011). This requires analyzing pharmacy prescription refill data. The literature varies 
on an exact percentage to be considered adherent, which is another issue related to measuring 
adherence, but most concur that an adherence rate of 80% or greater is considered adherent. The 
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Morisky scale is an eight-item, self-report measure of medication taking behavior. The criticism 
with this method of measurement is that patient’s tend to overestimate their adherence or 
deliberately misreport adherence to appear cooperative.  
Of the seven articles that I reviewed and synthesized, only one was specific to 
chemotherapy and neither of these scales was used in that study. Both of these scales have 
widespread use in the chronic disease setting and whether they could be applied to measure 
adherence in oncology patients is yet to be studied. The MEMS, which records time and date 
when a medication container is opened, is another measurement tool seen in the literature, 
however it is expensive and unlikely to see widespread use outside of clinical trials. Until further 
research is conducted, specifically on how best to measure adherence to oral chemotherapy, no 
recommendation can be made. 
Factors Affecting Adherence 
 For this review I examined 21 articles specific for factors influencing adherence to oral 
therapy; of these five were specific to oncology patients. There is a significant amount of 
research examining the reasons for patient’s non-adherence. My review revealed numerous 
factors. They include: (a) younger age (<45 years), (b) employed, (c) patient’s beliefs re: disease 
and/or treatment, (d) low self-efficacy, (e) cost, (f) drug regimen complexity, (g) dosing schedule 
and/or drug burden, (h) lack of drug information, (i) lack of social support, and (j) lack of health 
care professional support (see Appendix B, Table B1).  
Considering that this review did not include all possible research, it is possible there are 
more factors. However, I feel confident this is a fairly comprehensive list of the factors affecting 
adherence and they are the themes that repeated themselves in the literature which is the reason 
the decision was made not to include any further articles looking at factors influencing 
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adherence. One factor that I clearly identified in the research that affected adherence, depression 
and/or cognitive function, was an exclusion for this review and therefore was not included as a 
factor, but is clearly identified as contributing to non-adherence.  It is worth mentioning that the 
existing research often delineates between non-adherence being intentional versus non-
intentional. For example, a patient who chooses not to take their medication because it makes 
him or her sick is displaying intentional non-adherence versus a patient who simply forgets, 
which would be non-intentional non-adherence. This is an important factor to assess for because 
the interventions to support a patient are different depending on whether the non-adherence is 
intentional versus non-intentional. Non-adherence is often multi-factorial and assessing the 
reasons for patient non-adherence is necessary to tailor the appropriate interventions to improve 
it. 
Interventions to Improve Adherence 
 Twenty-three articles were reviewed for interventions to improve adherence, of which 
three were in oncology patients (see Appendix B, Table B2). This synthesis and review 
categorized the interventions by category. Those intervention categories are as follows: (a) 
education, (b) psycho-educational, (c) packaging, (d) self-monitoring, (e) reminders, (f) cost, (g) 
tailored, (h) targeted, (i) social support, (j) health care professional support, and (k) technology. 
Some data in the interventions categories was not clear-cut and what I found in one study to 
improve adherence was often contradicted in another. The ONS’ PEP classification schemas are 
decision rules for summative evaluation of a body of evidence (see Appendix C). This 
classification schema was developed by Mitchell and Friese, ONS members, to assist in 
evaluating a collective body of evidence about a health intervention for the purpose of informing 
decisions on implementation (Mitchell & Friese, n.d.). ONS PEP (Putting evidence into practice) 
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Weight of evidence classification schema decision rules for summative evaluation of a body of 
evidence. 
 There are three major components considered in classifying the collective evidence into 
one of six weight of evidence categories (Mitchell & Friese, n.d.). The first is quality of data 
with more weight assigned to higher levels of evidence such as randomized clinical trials and 
meta-analysis. The second is magnitude of the outcome (effect size or minimal clinically 
important difference) and the third is concurrence among the evidence. The six weight of 
evidence categories that will be used to make recommendations for practice are: (a) 
recommended for practice in which interventions for effectiveness has been demonstrated by 
strong evidence from rigorously-designed studies, meta-analysis, or systematic reviews, and for 
which expectation of harm is small compared with the benefits, (b) likely to be effective, in 
which interventions for the evidence is less well established than those listed under 
recommended for practice, (c) benefits balanced with harm in which interventions for which 
clinicians and patients should weigh up the beneficial and harmful effects according to individual 
circumstances and priorities, (d) effectiveness not established, in which the interventions 
currently have insufficient data or data of inadequate quality, (e) effectiveness unlikely, for 
interventions which lack of effectiveness is less well established than those listed under not 
recommended for practice, and (f) not recommended for practice, for interventions which 
ineffectiveness or harmfulness has been demonstrated by clear evidence, or the cost or burden 
necessary for the intervention exceeds anticipated benefit (Mitchell & Friese, n.d.).  
 Dr. Margaret Irwin and I reached the following recommendations for practice for 
interventions to improve adherence by consensus of two applying the PEP criteria. The 
categories were developed by identifying the themes in interventions to improve adherence and 
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grouping the results for ease of applying the criteria. The first category was education, which 
includes verbal or written instruction and effectiveness is not established. The second category 
was psycho-educational, which is education combined with a behavioral intervention and this is 
deemed likely to be effective. The third category was packaging, (pill boxes/blister packs) and 
this recommendation is likely to be effective. The fourth category was patient self-monitoring (of 
side effects) and this is likely to be effective. The fifth category was reminders (of any kind) and 
this category is recommended for practice. The sixth category was cost reduction (reducing co-
pay/assistance) and effectiveness not established. The seventh category was tailored 
interventions (pamphlets, letters, feedback) and likely to be effective. The eighth category was 
targeted interventions (phone reminder, computerized phone call, automated voice call, 
computer-aided instruction) and effectiveness is not established. The ninth category was social 
support and effectiveness is not established. The tenth category was health care professional 
support and effectiveness is not established. The eleventh and final category was technology 
driven interventions (interactive computer, automated voice response) and is likely to be 
effective.  
 It is significant to note that the only category of interventions that are recommended for 
practice (the highest recommendation) are reminders. This signifies that there is relatively strong 
evidence to show this intervention type matters. This should signify to the nurse that reminders 
have been shown by the evidence to improve adherence and she/he should consider 
incorporating this intervention into their patient teaching when appropriate. The recommendation 
of likely to be effective should also be considered as these interventions also matter, and does not 
mean there is not data to support their efficacy, rather the data is not as strong as that under 
recommended for practice. The types of interventions are many and varied and ultimately they 
34 
 
need to be individualized to each patient, keeping the evidence in mind. 
Discussion of Findings in the Context Of Literature and Frameworks 
 The framework that I used for this project was the JHNEBP model. In addition to 
applying the ONS PEP criteria for recommendations for practice, each article that I reviewed had 
the JHNEBP criteria applied to grade the strength and quality of the evidence. This project may 
continue on to become part of the ongoing work by the ONS PEP project team on oral 
adherence, so it was therefore more important for me to apply ONS’ classification schema 
criteria so this work could be considered for inclusion in the final resource developed by the 
team. 
  My review and synthesis on ways of measuring adherence demonstrated a lack of a 
consistent measurement tool to measure adherence to oral therapy. There was virtually no data 
on a valid measurement tool in the oncology setting. This was consistent with the literature that 
reports there is no gold standard to measure adherence (Sabate & WHO, p. 18) and no single 
measurement strategy has been deemed optimal (Sabate & WHO, p. 19).  
 The literature on factors contributing to non-adherence is rich. This included, although to 
a much lesser extent, some specific to the oncology patient. My review and synthesis revealed 
numerous factors contributing to non-adherence and that non-adherence is multi-factorial. 
Additionally, the importance of assessing for patient risk factors prior to the initiation of therapy 
became apparent to me as the approach to assisting patients to remain adherent is likely different 
depending on their risk assessment. The literature suggests that the reasons oncology patients are 
non-adherent are often similar to the reasons chronic disease patients are non-adherent. This is a 
significant finding because it then becomes reasonable to extrapolate the data on interventions 
that have been proven to improve adherence in chronic disease patients (this data is lacking 
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specific to oncology patients) to oncology patients. This conclusion is also reflected in the 
literature on factors contributing to non-adherence. Spoelstra and Given (2011) posited that 
clinicians needed to assess for risk factors that may influence adherence and play a key role in 
improving adherence by conducting ongoing assessment and measurement. 
  There have been a variety of studies examining interventions to improve adherence. 
Most are in the chronic disease patient although the research is currently increasing in this arena 
specific to the oncology patient as evidenced by the recent study by Spoelstra et al., (2013) 
examining an intervention to manage symptoms and adherence in patients on oral oncolytics. 
Based on this review and synthesis, there is minimal strong evidence around any single 
intervention to improve adherence. Many studies reviewed for this study had methodological 
flaws and were tested in very small populations (N<50). Therefore generalizations cannot be 
made. However, when synthesizing the interventions by category, there are clearly some 
interventions that should be considered for use in practice. 
 These findings are consistent with a review by Doggrell (2010) on adherence to 
medicines in the older-aged with chronic conditions that there are many unanswered questions 
about the most effective interventions for improving adherence. This project provided evidence 
for what was posited by Sabate & WHO (2003, p.11): that adherence problems are observed in 
all situations where the self-administration of treatment is required, regardless of type of disease, 
disease severity, and accessibility to health resources.  
 My synthesis served to identify several areas where more research is needed. First, what 
is an acceptable and valid measure of adherence? Second, what is the acceptable adherence 
threshold and if that number varies depending on the oral oncolytic? For example, for drugs that 
have a short half-life, missing a single dose may have more of an effect on disease progression 
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than missing a dose of a drug with a long half-life. Unlike the HIV literature, which has an 
answer to the adherence rate needed to keep the disease in check, oncology has yet to examine 
this issue. Third, what interventions improve adherence in the oncology patient? Although it may 
be determined by research that what helps chronic disease patients improve adherence also helps 
oncology patients and vice versa, until more research is conducted, only assumptions can be 
made. 
Implications 
Practice 
I have demonstrated that the research is lacking in the area of adherence specific to oral 
oncolytics. A major reason for this is the fact that there were a limited number of oral oncolytics 
on the market until recent years. A shift in research and development and subsequent approval of 
many oral oncolytics to market has created a new problem in the oncology arena. According to 
Foulon et al. (2011) the steady increase in the use of oral anticancer drugs has created a paradigm 
shift, challenging traditional attitudes towards cancer care and requiring new concepts of 
organization of oncology services. 
There is widespread attention to the issue across all oncology disciplines and the need for 
more research is apparent. As there is no definitive answer to the best way to measure adherence 
even in the chronic disease setting, research will be needed specific to oncology as to the best 
method for measuring adherence. Understanding the reasons why patients are non-adherent can 
contribute to developing interventions to improve adherence and my project uncovered common 
themes in the literature that provides a fairly comprehensive understanding of the reasons why 
patients are non-adherent. The vast majority of the literature is in the chronic disease setting. 
What is assumed but unconfirmed by research is if those same reasons can be generalized to the 
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oncology patient. Most of the literature that has looked at factors contributing to non-adherence 
in the oncology setting has been in the realm of estrogen receptor modulators and aromatase 
inhibitors. Although some of the reasons may be applied to all oncology disease states, it cannot 
be said for certainty. The standard of care for this population of breast cancer patients requires 
them to continue therapy for five years. The duration of therapy is a factor for non-adherence and 
this duration is not the case with other oncolytics that patients take until disease progression or 
unacceptable toxicities. In regards to interventions to improve adherence, there is a vast array of 
literature especially in cardiovascular, diabetes, and HIV. There is a significant need to increase 
the research being done to evaluate what interventions improve adherence specific to the 
oncology patient. By providing nurses with an evidence-based resource that they can employ in 
their practice, it is hoped that raising awareness and subsequent practice improvement around 
education and monitoring patients on oral chemotherapy will improve the quality of care 
provided to patients. 
Implications for Social Change in Practice 
The implications for social change are several. The first implication will be improved 
patient care if adherence rates can be improved and better health outcomes will likely follow. 
The final published outcome by the ONS PEP project team on oral adherence will provide nurses 
with an evidence-based resource that they can use to guide their practice and ultimately 
contribute to improving adherence. The second implication my project and the ongoing work by 
ONS will determine is what areas are lacking in the research in the hopes that the unanswered 
questions around adherence in the oncology patient can be studied. As the evidence develops it 
will assist health care professionals to know how best to assess and monitor adherence and those 
interventions to teach patients to assist them to remain adherent. The third implication, it is well 
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established that when patients are adherent, health care costs decrease. Considering all medicine 
related hospital admissions in the United States, 33%-69% are due to poor medication adherence 
with a resultant cost of approximately 100 billion a year to society (Osterberg & Blaschke, 
2005). Improving adherence can recognize not only an improvement in health outcomes but also 
a cost savings to society. Sabate & WHO (2003, p. 22) posit that investments in improving 
adherence are fully repaid with savings in healthcare utilization and the improvements in health 
outcomes fully justifies the investment. 
Health policy is an important way to recognize social change. A significant bill, titled 
Improving Cancer Treatment Education Act of 2012 HR 3790, has been re-introduced to 
Congress. In this bill it states that people with cancer benefit from having an education session 
with oncology nurses in advance of the initiation of treatment. Additionally in the bill it states 
that the Oncology Nursing Society has received reports from its members that because Medicare 
and other payers do no cover patient treatment education, patients and caregivers often do not 
receive adequate instruction before the initiation of therapy. ONS recommends that all patients 
being treated for cancer have a one-on-one educational session with a nurse in advance of 
beginning treatment. The bill also has language that speaks to the dichotomy of education that 
currently exists between infused chemotherapy and oral chemotherapy (Govtrack.us, 2012). 
Although education is just one piece to improving adherence, it is an important step in the right 
direction. It is my opinion that passage of this bill into law to provide reimbursement for patient 
education for chemotherapy teaching by a registered nurse will have a significant positive impact 
on patient care. 
A second policy issue is ensuring patients have access to oral chemotherapy without 
undue financial burden as compared to intravenous chemotherapy. State parity legislation for 
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oral chemotherapy drug coverage requires that insurance coverage for oral chemotherapy shall 
be provided on a basis no less favorable than coverage for injectable or intravenous 
chemotherapy. As of April 2013, twenty-two states and the District of Columbia have enacted 
oral chemotherapy access laws with another 11 pending legislation (International Myeloma 
Foundation, 2013). It is imperative that every state in the union has an oral chemotherapy parity 
law in place so that patients have access to the therapy they need and that is prescribed without 
financial hardship.  
 Lastly, public and healthcare payers are increasingly looking at the quality of cancer 
centers as determined by specialty designations and certifications. One way for cancer centers to 
demonstrate their commitment to high quality patient care is by achieving Quality Oncology 
Practice Initiative (QOPI) certification. The QOPI certification program is a three-year 
certification for outpatient hematology-oncology practices. It evaluates an individual practice’s 
performance in areas that affect patient care and safety (Quality Oncology Practice Initiative, 
(QOPI), n.d.a). Specific to this project are the measures around oral chemotherapy, including 
education provided prior to the start of therapy and monitoring of that therapy on subsequent 
visits (QOPI, n.d.b). It demonstrates that payers are recognizing the importance of quality 
measures and that education and monitoring of oral chemotherapy (to which is adherence is tied) 
is now being recognized as a quality measure. As more payers make it policy that in order to be 
on a plan’s preferred network and be eligible for payment, a practice will be required to 
demonstrate their commitment to quality, one way of which is through QOPI certification.  
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Project Strengths and Limitations 
Strengths 
My project had several strengths. First it is on a topic that is prominent and problematic 
in the oncology setting. Due to the lack of any significant research on the topic, this project was 
the foundation of ongoing work by the ONS to publish an evidence-based resource on oral 
adherence. Second, it was a systematic review and synthesis of the literature and the final 
outcome of a guideline on oral adherence that nurses can use in their practice to assist in 
providing evidence-based care. Third, the recommendations for practice were devised from the 
ONS PEP classification schema, which has a strong and respected history in performing 
systematic reviews and developing evidence-based PEP resources for nurses.  
Limitations 
This project was not without limitations. The project did not include all of the literature 
on oral adherence. The volume of literature on oral adherence in the chronic disease setting is 
vast and all of it could not be evaluated in the given time frame for this project. In hindsight, a 
better approach may have been to examine the literature just on interventions to improve 
adherence. Although a great deal of insight was provided in examining the measurement scales 
and factors contributing to non-adherence, it did not allow for fully examining any one entity in 
its entirety. Additionally, the amount of literature related to interventions is vast and the project 
may have been better served to look at specific categories of interventions in their totality. For 
example, evaluating the literature on all interventions that are tailored, targeted or technology 
based. Despite the limitations, this guideline provides nurses with guidance on oral adherence 
that they have not had available until now. 
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Analysis of Self 
Scholar 
When embarking on this project, just how encompassing a systematic review and 
synthesis of the literature would be was unknown to me. In retrospect, the goal was likely too 
lofty. This experience taught me the need as a scholar to have a clear vision of the end product 
desired and the path of how to best achieve that goal. It is not unusual to meet unforeseen 
obstacles and challenges and as a scholar I needed to be skilled at understanding and navigating 
this. My project as a DNP student epitomized the American Association of Colleges of Nurses 
Essential III for Essentials of Doctoral Education for Advanced Practice Nurses which speaks to 
using analytical methods to critically appraise existing literature and implement the best evidence 
for practice and applying the relevant findings to develop practice guidelines and improve 
practice and the practice environment (American Association of Colleges of Nurses, 2013, p. 
12). 
Practitioner 
As a practitioner, working on a topic area for almost a year increases knowledge 
exponentially. Although it can take years to become a subject matter expert, confidence and 
comfort with the subject have resulted from this project. With my increased knowledge, I am 
eager to share it with my colleagues and ignite a passion about the topic so that they will want to 
improve this clinical practice issue in their practices. Additionally, performing a systematic 
review and synthesis of the literature increases expertise in critiquing the literature. Prior to this I 
thought I was able to critically read research but quickly learned it is a skill that takes practice 
and instruction. Going through the critique process with my preceptor provided the opportunity 
to learn from her expertise in this area. Although there is always more to learn, I now feel 
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confident in my ability to critique, synthesize and draw my own independent conclusions about 
the literature. 
Project Developer 
As a project developer, there were several lessons learned. First is to take advantage of 
resources and let them be of help and be humble enough to ask for help when it is needed. 
Second is to have a realistic vision of what can be accomplished in a given time frame and what 
resources will be required to accomplish the goal. Also there is the skill required to maintain a 
time line and the flexibility to adjust when those unforeseen obstacles present themselves. Last is 
the ability to persevere and motivate people around you to be excited and willing to work on a 
project that isn’t necessarily their passion. 
Meaning for Future Project Development 
Adherence to oral oncolytics is a rising issue in the oncology setting and there is much 
work that needs to be done to improve this practice issue. The work to be done by the ONS 
project team will continue at least till the end of this year and likely into early next year. It is the 
expectation that I will continue to participate on this team after completion of this program and 
see their project to fruition. If in fact, a PEP resource is published by ONS, it may provide an 
opportunity to be published as a participant on this team. This topic is important to me and I 
would like to continue to increase my knowledge around it, be a part of developing solutions for 
it, and be recognized by my peers as a leader in the area of oral adherence. 
Summary and Conclusion 
Adherence to oral therapy has been a long-standing issue and challenge in the chronic 
disease setting. Despite significant research in this arena, little improvement has been seen in 
improving adherence in diseases such as cardiovascular, diabetes, and HIV. With the increase in 
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oral chemotherapy drugs and subsequent paradigm shift in cancer care treatment, adherence in 
the oncology patient is now being recognized as a clinical practice problem. Until the last 
decade, oncology patients were educated and monitored by oncology nurses in the infusion suite 
and practices were organized around this model of care. Patients prescribed oral chemotherapy 
often have no interaction with a nurse and the remedy would require a workflow redesign, which 
is not a simple or favored solution. This project started with the clinical practice problem of the 
lack of evidence to guide nurse’s practice on managing patient’s on oral oncolytics. The resultant 
guideline is a first step in providing nurses with the evidence to solving this practice problem. 
 Most of the research around adherence has been in the chronic disease setting and the 
best we can do is to apply that research to oncology until more research is conducted in the 
oncology setting. The final outcome of this project is a guideline for nurses to use as they interact 
with patients prescribed oral chemotherapy. The recommendations for practice should be 
considered and nurses should use this evidence and subsequent recommendations to guide their 
teaching and monitoring. It would seem futile to suggest interventions that have been shown not 
to improve adherence by the research. Conversely, nurses should consider those 
recommendations likely to be effective or recommended for practice and use this evidence to 
guide their interactions and education. 
 Adherence is important in all disease states to achieve the best clinical outcomes for 
patients, but possibly more so in oncology where a patient’s survival is dependent upon taking 
their medications as prescribed. Patient care is and will always be an inter-disciplinary effort; 
however nurses have always taken the lead in educating patients. Oncology nurses need to have 
an active role in conducting research, translating that research, and implementing it in the clinical 
setting to allow oncology patients to have the best possible outcome for their disease. This work 
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is a beginning step to provide nurses with the current state of the evidence and a guideline 
around oral adherence to employ in their interactions with patients on oral chemotherapy. 
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Section 5: Scholarly Product 
 Summary and Conclusions 
 This systematic review and synthesis of the literature revealed that there has been very 
little research conducted on adherence specific to oral oncolytics. As mentioned previously this 
is in large part due to the fact that there have been limited oral oncolytics on the market until the 
last several years so this observation is not surprising. However, there is a large amount of data 
on oral adherence in the chronic disease setting and until more research is conducted in the 
oncology patient that data will need to be extrapolated to the oncology patient.  
 The factors contributing to non-adherence have been well studied and the contributing 
factors to non-adherence are well elucidated in the literature. The majority of factors, such as age 
younger than 45 years, patient beliefs re: their disease and treatment, side effects, and cost just to 
name a few, are all contributing factors to non-adherence. The research demonstrated that some 
patients will have multiple contributing factors to non-adherence and some patients will have 
none. The factors identified were repeated in the majority of studies reviewed. Although it 
cannot be said with certainty, since the majority of the research has been conducted in the 
chronic disease setting, it is reasonable to assume that the factors contributing to non-adherence 
in patients with chronic disease are likely the same factors contributing to non-adherence in the 
oncology patient. Considering the increasing number of oral oncolytics now in use as part of 
cancer treatment, more research around the factors contributing to non-adherence specific to the 
oncology patient may shed new light specific to this patient type or confirm what has already 
been established in the chronic disease setting. 
 This literature review also critically appraised research on interventions to improve 
adherence. Again, there is a large volume of research done in this area in the chronic disease 
46 
 
setting, especially in HIV. The majority of studies reviewed established a lack of consistency in 
identifying any single intervention that is superior in improving adherence. Many of the studies 
were conducted in small numbers or in populations that do not allow for generalizations. The 
synthesis did support the use of reminders as the one category of intervention type that proved 
useful and improved adherence. As in factors contributing to non-adherence, the research is 
lacking specific to oncology patients and more research is needed specific to this patient 
population 
 This literature review and synthesis served to identify several areas where additional 
research is needed. Until that research is conducted, extrapolations from the chronic disease 
setting is reasonable to use as the evidence to guide nurse’s interactions with their patients 
receiving oral chemotherapy. The following is a guideline developed from the synthesis of this 
literature review on oral adherence and can be used by nurses to identify risk factors for non-
adherence and those interventions which have been shown to improve adherence based on the 
evidence. A first step in improving adherence is assessing for those risk factors that may 
influence adherence followed by individualized patient/caregiver teaching and this guideline is a 
tool that assists nurses to begin this process. 
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Guideline on Oral Adherence 
Background: Oral oncolytics continue to come to market at an unprecedented pace. Unlike 
intravenous chemotherapy, which is administered in the controlled environment of the 
chemotherapy suite and monitored by nurses, oral chemotherapy is administered in the patient’s 
home and shifts the burden of administration and monitoring to the patient. There is currently no 
gold standard definition of adherence. There is little information on how best to assess for 
adherence and the majority of research on interventions to improve adherence has been done in 
the chronic disease setting. In order for nurses to have an active role in improving this clinical 
challenge, they need to know the current evidence around adherence. This guideline will provide 
that evidence and recommendations for practice based on the systematic review and synthesis of 
evidence completed on oral adherence. 
Objective: To provide an evidence-based resource tool that nurses can employ in their practice 
to guide their patient interactions with adult patients who are on oral chemotherapy. It is intended 
to provide guidance for nurses to assess factors that may contribute to non-adherence and 
identify what interventions are effective to facilitate patient adherence. 
Search Methods: The literature was searched using Medline, PubMed, CINAHL, PsychInfo 
from 1997-2013. Additionally, reference lists of papers that were eligible for inclusion in the 
systematic review were scanned for additional citations. The literature search of the electronic 
databases combined the following terms: medication adherence and oncology and/or cancer 
and/or neoplasm and/or oral and/or chronic disease.  
Selection Criteria: The search included the following designs: systematic reviews, meta-
analysis, randomized controlled trials, and non-randomized comparative cohort studies. Articles 
were selected for inclusion in the evidence series if they reported data on factors contributing to 
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non-adherence and interventions to improve adherence. Case reports, letters, and editorials were 
not considered for inclusion. Additionally, articles that included pediatrics, depression, cognitive 
disorders, pregnancy, substance abuse, or clinical trials were excluded. 
Data Collection & Analysis: One author independently selected studies for inclusion and 
reviewed them. The evidence for factors affecting adherence was synthesized and the common, 
repeating factors were identified. Interventions to improve adherence were synthesized and 
grouped by category and the Oncology Nursing Society’s Putting Evidence into Practice 
classification schema was used to determine the weight of the evidence in order to develop 
recommendations for practice (see Appendix C). The classification schema was applied by two 
individuals by consensus. Fifty-one articles were included in this review. 
Main Results: Factors contributing to non-adherence: Numerous factors have been identified in 
the literature that contributes to non-adherence. They include: younger age, employed, drug 
burden, dosing schedule, patient’s belief system especially re: disease and treatment, side effects, 
lack of social and/or Health Care Provider support, lack of drug education, low self-efficacy, and 
cost. It is important to assess each patient individually for risk factors that may affect their ability 
to be adherent. Table B1 can be considered a quick reference card and can be used to serve as an 
assessment of these factors and assist in identifying those patients who may be at risk for non-
adherence. 
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Table 1 
Factors Contributing to Lack of Adherence 
Age younger than 
 45 years 
Side Effects Frequent dosing 
schedule & high oral 
drug burden 
Lack of social support 
Employed 
 
Low self-efficacy Complex drug regimen Lack of Health Care 
Provider support 
Patient beliefs re: 
disease (presence, 
seriousness) & 
treatment (necessity of 
it, efficacy) 
 
Cost 
 
 
Lack of drug 
information 
 
Interventions to improve adherence have been mostly studied in the chronic disease setting. 
Although the data is very limited specific to oncology patients, it is assumed that the 
interventions shown to improve adherence in the chronic disease setting are likely to improve 
adherence in the oncology patient. The interventions have been grouped by category and the 
recommendations for use have been based on synthesizing the weight of the evidence using the 
following classification schema: 
Recommended for practice 
Interventions for which effectiveness has been demonstrated by strong evidence from rigorously-
designed studies, meta-analysis, or systematic reviews, and for which expectation of harm is 
small compared with the benefits. 
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Likely to be effective 
Interventions for which the evidence is less well established than for those listed under 
recommended for practice. 
Benefits balanced with Harms 
Interventions for which clinicians and patients should weigh up the beneficial and harmful 
effects according to individual circumstances and priorities. 
Effectiveness not established 
Interventions for which there are currently insufficient data or data of inadequate quality. 
Effectiveness Unlikely 
Interventions for which lack of effectiveness is less well established than for those listed under 
not recommended for practice. 
Not recommended for practice 
Interventions for which ineffectiveness or harmfulness has been demonstrated by clear evidence, 
or the cost or burden necessary for the intervention exceeds anticipated benefit.
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Table 2 
Recommendations on Intervention Categories to Improve Adherence 
Author’s conclusions: There is little data around adherence to oral therapies in the oncology 
setting so some extrapolations are necessary from the plethora of literature on the topic in the 
chronic disease setting. Patients on oral anti-tumor therapy should be assessed for risk factors 
known to decrease adherence while recognizing that there are many factors that contribute to 
non-adherence. Some patients will have multiple factors while some may have none. Based on 
their risk factor, interventions to assist with improving adherence should be tailored to the 
patient’s risk factor while recognizing very few interventions have strong data to fully support 
their use. However, reminders have been shown to be effective and should be recommended if  
 
Education 
 
Effectiveness not established 
 
Psycho-educational 
 
Likely to be effective 
 
Packaging 
 
Likely to be effective 
 
Self-monitoring 
 
Likely to be effective 
 
Reminders 
 
Recommended for practice 
 
Cost 
 
Effectiveness not established 
Tailored information (pamphlets, letters, 
feedback, personalized info) 
 
Likely to be effective 
Targeted information (phone reminder, 
computerized phone call, auto voice call, 
personalized reminder, computer aided 
instruction) 
 
Effectiveness not established 
 
Social support 
 
Effectiveness not established 
 
Health Care Provider support 
 
Effectiveness not established 
Technology (interactive computer, phone, 
automated voice response)  
 
Likely to be effective 
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appropriate. The categories recommended as likely to be effective should be considered when 
appropriate, as there is evidence (not as strong as recommended for practice) to support their 
consideration with patients. With the increased use of oral oncolytics more research is needed to 
determine how best to measure adherence in the oncology setting and what interventions 
oncology patients find most helpful.
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Appendix B: Supporting Evidence for Guidelines on Oral Adherence 
Table B1 
 
Evidence Table for Factors Contributing to Lack of Adherence 
 Author Study Design 
Site 
info N Sample Findings Limitations 
FACTOR      
age Atkins et al., 2006 qualitative 
multi/ 
UK 131 
stable breast cancer, 2 
years post diagnosis 
 
mean age=59.4 years 
 
F=100% 
55% of woman reported non-adherence to 
mediation frequently or occasionally, with 
younger woman (95% CI, P=0.015) and those 
who disliked taking their medication (P=0.001) 
being significantly less adherent 
interview so pts 
may have said  
more desirable 
responses, didn't 
actually determine 
preferable route 
 Ediger et al., 2007 
longitudinal 
population 
based 
multi/ 
Canada 326 
diagnosis of IBD within 
previous 7 years 
 
median age=41 years 
 
M=40%, F=60% 
High adherence was reported by 73% of men and 
63% of women, for men, predictors of low 
adherence included diagnosis and employment 
status (full-time); for women, younger age was a 
predictor of low adherence 
self-report, 
volunteered, 
mostly 
Caucasian 
 Gatti et al., 2009 qualitative 
multi/ 
US 275 
used Grady Health 
System to pick up 
prescriptions, had been a 
patient for at least 6 
months 
 
avg age=53.9 years 
 
M=27%, F=73% 
 
Younger patients (<65 years) had 2.5 times greater 
odds (95% CI) of low med adherence than >65 
years.  
self-reported, 
mostly AA  
population 
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Table B1 
 
Evidence Table for Factors Contributing to Lack of Adherence 
 Author Study Design 
Site 
info N Sample Findings Limitations 
 Iihara et al., 2004 cross-sectional 
single/ 
Japan 154 
chronic primarily liver, 
GI or nervous system 
diseases who had been 
prescribed oral meds for 
regular use 
 
“approx 60 years” 
 
M=60%, F=40% 
51/154 showed intentional non-adherence, 
intentional non-adherence was associated with 1) 
patients beliefs with respect to taking med without 
anxiety )(P<0.001), 2) poor comprehension of 
general aspects of med (P<0.001), and 3) being in 
the prime of life (40-59years) (P=0.011).  
self-report, culture 
 Sedjo et al., 2010 
retrospective 
cohort 
multi/ 
US 13,593 
women continuously 
enrolled for at least 2 
years and had breast 
cancer diagnosis in their 
first year 
 
mean age= 55.5 years 
 
F=100% 
23% were non-adherent over 1 year; AI non-
adherence was associated with younger age 
(<45 years), out of pocket cost of >$30 per AI 
script as compared with <$10. 
filled Rx assumes 
taken 
 Tarantino et al., 2010  RCT 
single/ 
Italy 84 
inpatients without mental 
diseases who felt well 
enough to complete the 
questionnaire 
 
mean age=66.4 years 
 
M=44.3%, F=45.7% 
1 month post discharge 41.4% of uninformed 
patients reported nonadherence vs 20.5% of 
informed patients (P=0.03);younger age was 
associated with nonadherence (p=0.003); 
adherent patients perceived nonadherent behavior 
to be more dangerous (P=0.001) than adherent 
behavior and associated it with an absence of 
benefits (P=0.024). 
small sample, no 
attentional  
control, 
questionnaire made 
up by 
 investigators 
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Table B1 
 
Evidence Table for Factors Contributing to Lack of Adherence 
 Author Study Design 
Site 
info N Sample Findings Limitations 
 Tiv et al., 2012 qualitative 
multi/ 
France 3637 
claimed reimbursement 
for oral hypoglycemic 
agents and/or insulin at 
least 3 times between 
Aug 2006 & July 2007 
 
median age=64 years 
 
M-n=2138 
 
F-n=1499 
in univariate analysis many factors were associated 
with adherence, gender and time from diagnosis 
did not (P=0.93 and 0.90), working professionals 
more nonadherent than non working (30% vs 15%, 
P<0.001) and took med late more often (51% vs 
35%, P<0.001);  socio-demographic factors 
associated with poor vs good adherence: age <45 
years (odds ratio=5.2), non European 
geographical origin (OR=2.6), financial 
difficulties (OR=1.7), professionally active 
(OR=1.5). Health care related factors: difficulties 
taking med alone (OR=3.8), decision making by pt 
only (OR=3.3), poor acceptability of medical 
recommendations (OR=2.7), lack of social support 
(OR=2.5), need for information (OR=2.0), no 
confidence in future (OR=1.6), need for medical 
support (OR=1.6), f/u by specialist (OR=1.4). 
self-report, # of 
meds not known, 
self selected to 
participate,  
very lengthy 
survey 
disliked 
med 
Atkins et al., 
2006 qualitative 
multi/ 
UK 131 
stable breast cancer, 2 
years post diagnosis 
 
mean age=59.4 years 
 
F=100% 
55% of woman reported non-adherence to 
mediation frequently or occasionally, with younger 
woman (95% CI, P=0.015) and those who 
disliked taking their medication (P=0.001) 
being significantly less adherent 
interview so pts 
may have said  
more desirable 
responses, didn't  
actually determine 
preferable route 
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Table B1 
 
Evidence Table for Factors Contributing to Lack of Adherence 
 Author Study Design 
Site 
info N Sample Findings Limitations 
personality Axelsson et al., 2011 qualitative 
homes/ 
Sweden 749 
individuals who reported 
diagnosed chronic 
disease 
 
median age=53.5 years 
 
M=43%, F=57% 
Negative relationship between Neuroticism and 
medication non-adherence  (P=0.0011), while both 
Agreeableness (P=0.001) and Conscientiousness 
(0.0.36) were positively related to adherence 
low response rate, 
random sample 
dosing 
schedule 
Bae et al., 
2012 
retrospective 
cohort database 
analysis 
multi/ 
US 1,077,474 
CVD with prescription 
for antidiabetic, 
antihyperlipi-demic 
antiplatelet, or cardiac 
agent 
 
avg age=59 
 
M=51%, F=49% 
The adjusted mean mediation possession ratio 
(MPR) _+ standard error value for QD agents was 
13.6% greater than BID agents (P<0.01). The 
adjusted mean MPR value for QD agents was 
2.9%, 17.5%, and 29.4% greater than BID agents 
in the antidiabetic, antihyperlipidemic, and 
anitplatelet therapeutic classes. For cardiac agents, 
the adjusted mean MPR value was similar between 
QD and BID agents.  
patients may get 
Rx filled at low  
cost generic 
pharmacy and not 
show  pharmacy 
claim (pay cash) 
drug 
burden 
Benner et al., 
2009 
 Retrospective 
database 
analysis 
multi/ 
US 5759 
patient enrollees in 
managed care 
organizations who were 
new users of 
antihypertensive and 
lipid lowering therapy 
 
50%>65 years 
 
M=52.3%, F=47.7% 
Patients with 0 ,1 and 2 prior meds, 41%, 35%, 
30% were adherent; among patients with 8, 9, and 
>10  medications, 20.1%, 25.5%, and 20.1% were 
adherent; as number of meds goes up, adherence 
goes down 
assume Rx filled 
means taken,  
may have rec'd 
samples or pd cash  
would contribute to 
underadherence 
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Table B1 
 
Evidence Table for Factors Contributing to Lack of Adherence 
 Author Study Design 
Site 
info N Sample Findings Limitations 
 Efficace et al., 2012 qualitative 
multi/ 
Italy 413 
diagnosed in early 
chronic phase of CML 
and been in treatment 
with imatinib for at least 
3 years 
 
median age=56.8 years 
 
M=59.56%, F=40.44% 
 53% of patients reported optimal adherence 
behavior,  multivariate model showed 
concomitant drug burden (pts already on other 
meds may more easily add another) (P=0.006) 
greater level of social support (P<0.001) and 
satisfaction with information received (P<0.001) 
associated with optimal adherence. 
adapted version of 
MMAS,  
self-report 
beliefs Bhattacharya et al., 2012 qualitative 
single/ 
UK 43 
dx with breast or 
colorectal cancer and 
prescribed Capecitabine 
 
mean age=64.5 years 
 
M=44.2%, F=55.8% 
Non-adherence was reported by 23.3% of the 43 
participants. Capecitabine was perceived necessary 
by 97.6%, but almost one-third of participants had 
strong concerns. Side effects were reported by 
80% of participants, with PPE and fatigue most 
troubling participants. Complete satisfaction with 
information received was reported by 65% of 
participants, however, dissatisfaction about how to 
tell if Capecitabine is working and the proposed 
duration of therapy was expressed by 42.9% and 
37.3% of participants, respectively. 
small sample, 
single site,  
self-report 
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Table B1 
 
Evidence Table for Factors Contributing to Lack of Adherence 
 Author Study Design 
Site 
info N Sample Findings Limitations 
 Gatti et al., 2009 qualitative 
single/ 
US 275 
used Grady Health 
System to pick up 
prescriptions, had been a 
patient for at least 6 
months 
 
avg age=53.9 years 
 
M=27%, F=73% 
 
Negative beliefs about meds had 2.1 greater odds 
(95% CI) of low med adherence compared with 
patients with less negative beliefs 
self-reported, 
mostly AA  
population 
 Horne et al., 1999 
cross-sectional 
web survey 
multi/ 
UK 324 
chronic illness groups 
prescribed 1 or more for 
regular use in treatment 
in their illness for at least 
2 months prior to study 
 
mean 45.4-63.6 years 
 
M=37%-71% 
F= 29%-63% 
Age and gender rates 
vary depending on illness 
group 
 
 
Beliefs about medicines were related to reported 
adherence; higher necessity scores correlated with 
higher reported adherence (r=0,21, P<0.01) and 
higher concerns correlated with lower reported 
adherence (r=0.33, P<0.001);  gender, educational 
experience, or number of prescribed medicine did 
not predict reported adherence. 
self-report, can't be 
sure about  
direction of 
causality b/w 
beliefs 
and behavior 
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Table B1 
 
Evidence Table for Factors Contributing to Lack of Adherence 
 Author Study Design 
Site 
info N Sample Findings Limitations 
 Iihara et al., 2004 cross-sectional 
single/ 
Japan 154 
chronic primarily liver, 
GI or nervous system 
diseases who had been 
prescribed oral meds for 
regular use 
 
“approx 60 years” 
 
M=60%, F=40% 
51/154 showed intentional non-adherence 
,intentional non-adherence was associated with 1) 
patients beliefs with respect to taking med 
without anxiety )(P<0.001), 2) poor 
comprehension of general aspects of med 
(P<0.001), and 3) being in the prime of life (40-
59years) (P=0.011).  
self-report, culture 
 Mann et al., 2009 qualitative 
single/ 
US 151 
Type 2 diabetes for at 
least 6 months who were 
prescribed diabetes 
medication 
 
median age=57 years 
 
M=32%, F=57% 
predictors of poor adherence were believing you 
have diabetes only when your sugar is high, saying 
there was no need to take medicine when the 
glucose was normal, worrying about side-effects 
of diabetes medicines, lack of self-confidence in 
controlling diabetes, and feeling medicines are 
hard to take.  
self-report, inner 
city population 
 not generalizable 
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Table B1 
 
Evidence Table for Factors Contributing to Lack of Adherence 
 Author Study Design 
Site 
info N Sample Findings Limitations 
 McHorney et al., 2010 qualitative 
multi/ 
US 19,023 
one of six chronic 
diseases: asthma, 
diabetes, 
hyperlipidaemia, 
hyptertension, 
osteoporosis, or other 
cardiovascular disease 
 
median age=59 years 
 
gender not specified 
same four reasons were most commonly reported 
for both medication non-fulfillment and 
medication non-persistence: paying for the med a 
financial hardship (56 & 43%), fear or experience 
of side effects (46 & 35%), generic concerns about 
meds(32 & 23%), and lack of perceived need for 
the med(25 & 23%). 
not generalizable 
based on study 
population to US 
population, 
self-report, limited 
responses to 10 
for non-fulfillment 
and 12 for 
non-persistence 
(could have been 
more reasons) 
 Saratsioutou  et al., 2010 
prospective 
observational 
multi/ 
Greece 99 
ca patients visiting the 
study centers pharmacy 
or MD’s to obtain their 
oral med 
 
median age=61 years 
 
M=37%, F=62% 
19 patients reported unintended non-adherence, 
most important factor relating to unintended 
nonadherence was patient’s belief regarding 
treatment effectiveness since only 16.7% of the 
patients believing that their treatment is effective 
reported nonadherence as opposed to 62.5% for 
those that did not believe the treatment is effective 
(P=0.03). Intentional nonadherence was reported 
by 14 patients. The most important factor 
correlating to intentional nonadherence was time 
since disease diagnosis, as nonadherence was 
reported by 33.3% of patients having the disease 
less than 6 months compared to 16.7% for those 
between 6-24 months and 8.3% for those between 
2-5 years (p=0.01). 
small sample, self-
report 
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Table B1 
 
Evidence Table for Factors Contributing to Lack of Adherence 
 Author Study Design 
Site 
info N Sample Findings Limitations 
 Tarantino et al., 2010 
prospective 
randomized 
single/ 
Italy 84 
inpatients without mental 
diseases who felt well 
enough to complete the 
questionnaire 
 
mean age=66.4 years 
 
M=44.3%, F=45.7% 
1 month post discharge 41.4% of uninformed 
patients reported nonadherence vs 20.5% of 
informed patients (P=0.03);younger age was 
associated with nonadherence (p=0.003); 
adherent patients perceived nonadherent 
behavior to be more dangerous (P=0.001) than 
adherent behavior and associated it with an 
absence of benefits (P=0.024). 
small sample, no 
attentional 
control,  
questionnaire made 
up by 
 investigators 
 Unson et al., 2003 focus group 
single/ 
US 95 
age 60 or older not on 
treatment for 
osteoporosis 
 
avg age=74.8 years 
 
F=100% 
Adherence was associated with recognition of the 
serious consequences of nonadherence, realization 
of the beneficial efforts, and the belief that 
medicines are not harmful. 
small sample, ? If 
there was fair 
balance of drugs 
presented, not 
enough 
sociodemographic 
data, 
 interviewers 
background 
dissimilar  
to participants 
side effects Bhattacharya  et al., 2012 qualitative 
single/ 
UK 43 
dx with breast or 
colorectal cancer and 
prescribed Capecitabine 
 
mean age=64.5 years 
 
M=44.2%, F=55.8% 
Side effects were reported by 80% of participants, 
with PPE and fatigue most troubling participants 
(did not tie to adherence measure). 
small sample, 
single site,  
self-report 
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Table B1 
 
Evidence Table for Factors Contributing to Lack of Adherence 
 Author Study Design 
Site 
info N Sample Findings Limitations 
 McHorney et al., 2010 qualitative 
multi/ 
US 19,023 
one of six chronic 
diseases: asthma, 
diabetes, 
hyperlipidaemia, 
hyptertension, 
osteoporosis, or other 
cardiovascular disease 
 
median age=59 years 
 
gender not specified 
same four reasons were most commonly reported 
for both medication non-fulfillment and 
medication non-persistence: paying for the med a 
financial hardship (56 & 43%), fear or experience 
of side effects (46 & 35%), generic concerns 
about meds(32 & 23%), and lack of perceived 
need for the med(25 & 23%). 
not generalizable 
based on study 
population to US 
population, 
self-report, limited 
responses to 10 
for non-fulfillment 
and 12 for  
non-persistence 
(could have been  
more reasons) 
 Hauber et al., 2009 
cross-sectional 
web survey 
multi/ 
US & 
UK 
407 
type 2 diabetes currently 
using GLM and not using 
insulin or Exenatide 
 
mean age=57 years 
 
M=62%, F=38% 
With no wt gain or CV risk, adherence was 73.5%, 
wt gain of 9 kg decreases adherence by 30%, a 1 
% point increase in heart attack risk results in 
16.5% decrease in adherence. 
evaluating 
hypothetical 
choices,  
poss selection bias 
cost Briesacher et al., 2009 
retrospective 
database 
review 
multi/ 
US 327,629 
starting generic drug 
therapy 
 
mean age=56 years 
 
M=46.8%, F= 53.2% 
Generic prescribing was associated with modestly 
improved adherence in 2 of 5 study conditions. 
Co-payments of $0 were associated with improved 
adherence across all conditions. 
overlap of chronic 
conditions, 
assume filled 
means taken 
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Table B1 
 
Evidence Table for Factors Contributing to Lack of Adherence 
 Author Study Design 
Site 
info N Sample Findings Limitations 
 McHorney et al., 2010 qualitative 
multi/ 
US 19,023 
one of six chronic 
diseases: asthma, 
diabetes, hyperlipidemia, 
hyptertension, 
osteoporosis, or other 
cardiovascular disease 
 
median age=59 years 
 
gender not specified 
same four reasons were most commonly reported 
for both medication non-fulfillment and 
medication non-persistence: paying for the med a 
financial hardship (56 & 43%), fear or 
experience of side effects (46 & 35%), generic 
concerns about meds(32 & 23%), and lack of 
perceived need for the med(25 & 23%). 
not generalizable 
based on study 
population to US 
population,  
self-report, limited 
responses to 10  
for non-fulfillment 
and 12 for 
non-persistence 
(could have been 
more reasons) 
 Sedjo et al., 2010 
retrospective 
cohort 
multi/ 
US 13,593 
women continuously 
enrolled for at least 2 
years and had breast 
cancer diagnosis in their 
first year 
 
mean age=55.5 years 
 
F=100% 
23% were non-adherent over 1 year; AI non-
adherence was associated with younger age (<45 
years), out of pocket cost of >$30 per AI script 
as compared with <$10. 
filled Rx assumes 
taken 
obstacles Ediger et al., 2007 
longitudinal 
population 
based 
multi/ 
Canada 326 
diagnosis of IBD within 
previous 7 years 
 
median age=41 years 
 
M=40%, F=60% 
strongest predictor of adherence was the measure 
of obstacles to adherence, the more obstacles, the 
more likely to have low adherence.  
self-report, 
volunteered, 
mostly  
Caucasian 
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Table B1 
 
Evidence Table for Factors Contributing to Lack of Adherence 
 Author Study Design 
Site 
info N Sample Findings Limitations 
 Norton et al., 2010 qualitative 
multi/ 
US 327 
HIV positive, currently 
prescribed ARV meds 
 
Median age=45 years 
 
Unintentional non-adh 
group M=58.6%, 
F=41.4% 
8.9% (29) reported taking a break without talking 
to their HCP and classified as intentional non-
adherent, 298 were unintentional non-adherent. 
Few differences were observed between 
intentional vs unintentional non-adherers on 
demographic variables, adherence-related 
information, or motivation. Numerous differences 
observed between groups on adherence-related 
behavioral skills (14 questions around how 
hard or easy is it for you to…).  
self-report, pts may 
not have  
appropriately 
answered single  
question that 
classified them as 
 intentional or 
unintentional 
 Tiv et al., 2012 qualitative 
multi/ 
France 3637 
claimed reimbursement 
for oral hypoglycemic 
agents and/or insulin at 
least 3 times between 
Aug 2006 & July 2007 
 
median age=64 years 
 
M-n=2138 
 
F-n=1499 
in univariate anaylsis many factors were associated 
with adherence, gender and time from diagnosis 
did not (P=0.93 and 0.90), working professionals 
more nonadherent than non working (30% vs 
15%, P<0.001) and took med late more often 
(51% vs 35%, P<0.001);  socio-demographic 
factors associated with poor vs good adherence: 
age <45 years (odds ratio=5.2), non European 
geographical origin (OR=2.6), financial 
difficulties (OR=1.7), professionally active 
(OR=1.5). Health care related factors: difficulties 
taking med alone (OR=3.8), decision making by pt 
only (OR=3.3), poor acceptability of medical 
recommendations (OR=2.7), lack of social support 
(OR=2.5), need for information (OR=2.0), no 
confidence in future (OR=1.6), need for medical 
support (OR=1.6), f/u by specialist (OR=1.4). 
self-report, # of 
meds not known, 
self selected to 
participate, very 
lengthy survey 
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Table B1 
 
Evidence Table for Factors Contributing to Lack of Adherence 
 Author Study Design 
Site 
info N Sample Findings Limitations 
drug info/ 
education 
Efficace et 
al., 2012) qualitative 
multi/ 
Italy 413 
diagnosed in early 
chronic phase of CML 
and been in treatment 
with Imatinib for at least 
3 years 
 
median age=56.8 years 
 
M=59.56%, F=40.44% 
53% of patients reported optimal adherence 
behavior,  multivariate model showed drug burden 
((P=0.006) greater level of social support 
(P<0.001) and satisfaction with information 
received (P<0.001) associated with optimal 
adherence. 
adapted version of 
MMAS, 
self-report 
 Iihara et al., 2004 cross-sectional 
single/ 
Japan 154 
chronic primarily liver, 
GI or nervous system 
diseases who had been 
prescribed oral meds for 
regular use 
 
“approx 60 years” 
 
M=60%, F=40% 
51/154 showed intentional non-adherence, 
intentional non-adherence was associated with 1) 
patients beliefs with respect to taking med without 
anxiety )(P<0.001), 2) poor comprehension of 
general aspects of med (P<0.001), and 3) being 
in the prime of life (40-59years) (P=0.011) 
self-report, culture 
 Regnier et al., 2011 qualitative 
multi/ 
France 45 
taking Capecitabine 
 
mean age=65.4 years 
 
M=12%, F=88% 
 Patients said MD’s gave little information about 
treatment, doctors gave different amounts of 
information and most important difference was 
about major side effects and how to manage. 
small sample, 
attentional control,  
selection bias 
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Table B1 
 
Evidence Table for Factors Contributing to Lack of Adherence 
 Author Study Design 
Site 
info N Sample Findings Limitations 
Social/ 
HCP 
support 
Efficace et 
al., 2012) qualitative 
multi/ 
Italy 413 
diagnosed in early 
chronic phase of CML 
and been in treatment 
with Imatinib for at least 
3 years 
 
median age=56.8 years 
 
M=59.56%, F=40.44% 
53% of patients reported optimal adherence 
behavior,  multivariate model showed drug burden 
((P=0.006) greater level of social support 
(P<0.001) and satisfaction with information 
received (P<0.001) associated with optimal 
adherence. 
adapted version of 
MMAS,  
self-report 
 Tiv et al., 2012 qualitative 
multi/ 
France 3637 
claimed reimbursement 
for oral hypoglycemic 
agents and/or insulin at 
least 3 times between 
Aug 2006 & July 2007 
 
median age=64 years 
 
M-n=2138 
 
F-n=1499 
in univariate analysis many factors were associated 
with adherence, gender and time from diagnosis 
did not (P=0.93 and 0.90), working professionals 
more nonadherent than non working (30% vs 15%, 
P<0.001) and took med late more often (51% vs 
35%, P<0.001);  socio-demographic factors 
associated with poor vs good adherence: age <45 
years (odds ratio=5.2), non European geographical 
origin (OR=2.6), financial difficulties (OR=1.7), 
professionally active (OR=1.5). Health care related 
factors: difficulties taking med alone (OR=3.8), 
decision making by pt only (OR=3.3), poor 
acceptability of medical recommendations 
(OR=2.7), lack of social support (OR=2.5), need 
for information (OR=2.0), no confidence in future 
(OR=1.6), need for medical support (OR=1.6), 
f/u by specialist (OR=1.4). 
self-report, # of 
meds not known, 
self selected to 
participate, 
very lengthy 
survey 
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Table B1 
 
Evidence Table for Factors Contributing to Lack of Adherence 
 Author Study Design 
Site 
info N Sample Findings Limitations 
self-
efficacy 
Gatti et al., 
2009 
qualitative single/ 
US 
275 used Grady Health 
System to pick up 
prescriptions, had been a 
patient for at least 6 
months 
avg age=53.9 years 
M=27%, F=73% 
Patients with lower self-efficacy had 4.3 times 
greater odds (95% CI) of low med adherence 
compared with patients with higher self-efficacy. 
self-reported, 
mostly  
AA population 
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Table B2 
 
Evidence Table for Recommendations on Intervention Categories to Improve Adherence 
 Author Study Design Site info N Sample Findings Limitations 
Intervention: Education. Recommendation: Effectiveness not established 
 
Konkle-
Parker 
et al., 2008 
randomized pilot single/ US 56 
starting ART for 1st time 
or restarting after at least 6 
months off med 
 
age=not stated 
 
M=63%, F=37% 
At V-1 (1 mo after enrollment) adherence by 
electronic measurement was 74.8%, 84.9% by 
3 day recall and 90.3% by 3-4 wk VAS. At V-
2 (3 mo later) and V-3 (3 months after V-2) 
self-reported adherence was consistently 
100%; the electronic measurement showed 
adherence rates ranging from 75-100% (V-2) 
and 60-86% at V-3. Significant correlation at 
V-1 between MEMS and other methods of 
measurement with r=0.611 with 3 day recall 
(p=0.046) and r-0.793 with VAS measurement 
(p=0.004 
small sample, 
transient, low-
income 
population, very 
high attrition 
rate, 89% AA 
population 
 Conn et al., 2009 
Meta 
analysis 
multi/ 
not 
stated 
16-6,813 
meds to treat chronic 
conditions in>60 years old 
 
median age=67 years 
 
in studies reporting 
gender, F>50% of sample 
Neither med nor disease education had any 
impact on effect size however, interventions 
with succinct written instructions achieved 
better effects on MA (SMD=0.61) than studies 
without succinct written instructions 
(SMD=0.29). The difference between 
providing any written directions (SMD=0.45 
and no written directions (SMD=0.28) was not 
significant. 
Small number of 
retrieved articles, 
RCT only, high 
heterogeneity, no 
CI listed 
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Table B2 
 
Evidence Table for Recommendations on Intervention Categories to Improve Adherence 
 Author Study Design Site info N Sample Findings Limitations 
 Williams et al., 2008 systematic review 
multi/ 
global 20-472 
multiple chronic 
conditions 
 
age=mostly >70 years 
 
gender not specified 
3/8 used education (pharm f/u) (1+, 2-) 
No qualitative 
studies, small 
number  
of studies, 
studies done in 
mostly  
over 70 years of 
age 
 Peterson et al., 2003 
Meta 
analysis 
multi/ 
not 
stated 
36-12,424 
Pt/consumer that had 
intervention directed at 
them; effect of tools and 
methods designed to 
enhance medication 
adherence that have been 
evaluated in RCT 
 
Articles reviewed did not 
consistently report subject 
characteristics 
Educational interventions: 7/22 was oral 
teaching by MDs, in 5 cohorts pharmacist did 
and nurses in 4; other interventions were 
written or telephone education, mailed 
material, emailed material, AV education-no 
difference among intervention types r/t ES 
(p=0.441). 
Lack of 
consistent data 
and 
well-controlled 
trials, lack of  
consistent 
definition of 
adherence 
Intervention: Psycho-educational. Recommendation: likely to be effective 
 Kamau et al., 2011 
prospective 
descriptive 
multi/ 
Kenya 354 
men and women living 
with HIV undergoing ART 
 
age-42% 31-40 years 
 
M=28.6%, F=71.4% 
 positive relationship between coping self-
efficacy and adherence to ART (p<0.05) 
self-report, 
convenience 
sample 
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Table B2 
 
Evidence Table for Recommendations on Intervention Categories to Improve Adherence 
 Author Study Design Site info N Sample Findings Limitations 
 Peterson et al., 2003 
Meta 
analysis 
multi/ 
not 
stated 
 36-12,424 
Pt/consumer that had 
intervention directed at 
them; effect of tools and 
methods designed to 
enhance medication 
adherence that have been 
evaluated in RCT 
 
Articles reviewed did not 
consistently report subject 
characteristics 
Behavioral interventions: 20/41 interventions 
had dosage-schedule changes as primary 
behavioral intervention, 11 had packaging 
changes, 4 had telephone reminders, 6 had 
other-no difference among groups r/t ES 
(p=0.91) 
Lack of 
consistent data 
and  
well-controlled 
trials, lack of  
consistent 
definition of 
adherence 
combined 
(educ w/ 
behavioral) 
Peterson et 
al., 2003 
Meta 
analysis 
multi/ 
not 
stated 
 36-12,424 
Pt/consumer that had 
intervention directed at 
them; effect of tools and 
methods designed to 
enhance medication 
adherence that have been 
evaluated in RCT 
 
Articles reviewed did not 
consistently report subject 
characteristics 
Combined interventions:  (oral education in 
combo with behavioral) ES was 0.08 (95% 
CI), mail reminders had largest impact (ES 
0.38), skill building (0.17), packaging changes 
(0.14), dose schedule changes (0.12) 
Lack of 
consistent data 
and 
 well-controlled 
trials, lack of  
consistent 
definition of 
adherence 
Intervention: Packaging. Recommendation: likely to be effective 
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Table B2 
 
Evidence Table for Recommendations on Intervention Categories to Improve Adherence 
 Author Study Design Site info N Sample Findings Limitations 
 Macintosh et al., 2006 
randomized 
prospective 
crossover 
single/ 
Canada 18 
solid tumors and were 
planned to receive at least 
2 consecutive cycles of 
Capecitabine 
 
median age=64 years 
 
M-n=3, F-n=15 
Adherence rates were similar with the two, 
81% with daily pill boxes and 86% with 
conventional pill bottles however more 
patients were satisfied with daily pill boxes 
and thought daily box was more helpful in 
reminding them to take their medications. 
small sample, 
had to track with 
diary 
card which may 
have served as 
 reminder and 
increased 
adherence 
 Conn et al., 2009 
Meta 
analysis 
multi/ 
not 
stated 
16-6,813 
meds to treat chronic 
conditions in>60 years old 
 
median age=67 years 
 
in studies reporting 
gender, F>50% of sample 
Packaging: MA interventions that included 
med packaging changes (pillboxes, pill 
cassettes, blister packs, special containers that 
indicate time of dose) were associated with 
larges ES (SMD=0.67) than interventions that 
did not include packaging changes 
(SMD=0.30).s were satisfied with daily pill 
boxes (61% vs 11%, P=0.027), preferred daily 
pill boxes (61% vs 17%, P=0.061) and thought 
daily pill boxes were more helpful in 
reminding them to take meds (50% vs 11%, 
P=0.070) 
Small number of 
retrieved articles, 
RCT only, high 
heterogeneity, no 
CI listed 
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Table B2 
 
Evidence Table for Recommendations on Intervention Categories to Improve Adherence 
 Author Study Design Site info N Sample Findings Limitations 
 Williams et al., 2008 systematic review 
multi/ 
global 20-472 
multiple chronic 
conditions 
 
age=mostly >70 years 
 
gender not specified 
1 study- IG-95.5% med adh, CG-69%, 
P<0.001 
No qualitative 
studies, small 
number 
of studies, 
studies done in 
mostly  
over 70 years of 
age 
Intervention: Self-monitoring. Recommendation: likely to be effective 
 Conn et al., 2009 
Meta 
analysis 
multi/ 
not 
stated 
16-6,813 
meds to treat chronic 
conditions in>60 years old 
 
median age=67 years 
 
in studies reporting 
gender, F>50% of sample 
Interventions that directed participants to self-
monitor symptoms r/t meds were more 
effective (SMD=1.18) than interventions that 
did not include this component (SMD=0.30).  
Small number of 
retrieved articles, 
RCT only, high 
heterogeneity, no 
 CI listed 
Intervention: Reminders. Recommendation: recommended for practice 
(tech) Conn et al., 2009 
Meta 
analysis 
multi/ 
not 
stated 
16-6,813 
meds to treat chronic 
conditions in>60 years old 
 
median age=67 years 
 
in studies reporting 
gender, F>50% of sample 
Interventions that included a stimulus to take 
med (electronic device that makes sound) were 
more effective (SMD=1.06) than interventions 
without cues (SMD=0.30). 
Small number of 
retrieved articles, 
RCT only, high 
heterogeneity,  
no CI listed 
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Table B2 
 
Evidence Table for Recommendations on Intervention Categories to Improve Adherence 
 Author Study Design Site info N Sample Findings Limitations 
 Revere et al., 2001 systematic review 
multi/ 
not 
stated 
11-12,391 
ambulatory patients 
 
pt characteristics not 
identified 
The interventions were categorized as mobile 
communications (3 studies, all positive), 
computer systems (9 studies, all positive), 
automated telephone communications (10 
studies, 9 positive, 1 negative) 
No cutting edge 
technology 
studied, 
mostly health 
behaviors vs 
meds 
(nontech) Revere et al., 2001 systematic review 
multi/ 
not 
stated 
11-12,391 
ambulatory patients 
 
pt characteristics not 
identified 
print communications-24 studies, 20 positive, 
4 negative 
No cutting edge 
technology 
studied, 
 mostly health 
behaviors vs 
meds 
Intervention: Cost. Recommendation: effectiveness not established 
 Farley et al., 2012 
Retrospective,  
pre-post quasi-
experimental study 
design with a 
nonequivalent 
control group 
multi/ 
US 
total not 
specified 
but ind 
drug 
classes had 
many 
thousands 
enrollees taking 1 of 8 
classes of drugs  
 
mean age 
participants=51.6, non 
part=52.2 years 
 
M=36-57%, F=43-64%-
varied by drug class 
Value Based Insurance Design (VBID) was 
associated with improved med adherence 
ranging from 1.4% to 3.2% at 1 year, which 
increased to 2.1% to 5.2% 2 years following 
VBID adoption. Adherence changes were most 
notable among patients who were non-
adherent before VBID implementation. 
assumption that 
rx filled means 
taken 
Intervention: Tailored. Recommendation: likely to be effective 
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Table B2 
 
Evidence Table for Recommendations on Intervention Categories to Improve Adherence 
 Author Study Design Site info N Sample Findings Limitations 
tailored Conn et al., 2009 
Meta 
analysis 
multi/ 
not 
stated 
16-6,813 
meds to treat chronic 
conditions in>60 years old 
 
median age=67 years 
 
in studies reporting 
gender, F>50% of sample 
Interventions that were individually tailored to 
specific participant characteristics were less 
effective (SMD=0.06) than interventions that 
were more standardized (SMD=0.37).Neither 
minutes of intervention nor number of 
intervention sessions affected mean ES. Mean 
predicted ES was highest for interventions 
delivered for 4 weeks (ES approx 0.7) but 
markedly reduced when interventions were 
either of brief duration or very prolonged 
Small number of 
retrieved articles, 
RCT only, high 
heterogeneity, no 
CI listed 
 Revere et al., 2001 Systematic review 
multi/ 
not 
stated 
11-12,391 
ambulatory patients 
 
pt characteristics not 
identified 
Of the 23 tailored intervention studies, 22 
reported improved outcomes, 15 of these were 
statistically significant.  
 
No cutting edge 
technology 
studied, 
mostly health 
behaviors vs 
meds 
 Williams et al., 2008 Systematic review 
multi/ 
global 20-472 
multiple chronic 
conditions 
 
age=mostly >70 years 
 
gender not specified 
 
4/8 studies used tailored intervention (not 
specified other than tailored) (1+, 3-), 
No qualitative 
studies, small 
number 
of studies, 
studies done in 
mostly 
over 70 years of 
age, pharm not 
blinded in one of 
these studies 
Intervention: Targeted. Recommendation: effectiveness not established 
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Table B2 
 
Evidence Table for Recommendations on Intervention Categories to Improve Adherence 
 Author Study Design Site info N Sample Findings Limitations 
 Revere et al., 2001 Systematic review 
multi/ 
not 
stated 
11-12,391 
ambulatory pts 
 
pt characteristics not 
identified 
14 used targeted interventions,  11 of targeted 
intervention studies reported improved 
outcomes, 6 of these were statistically 
significant 
No cutting edge 
technology 
studied, 
mostly health 
behaviors vs 
meds 
Intervention: Social Support (SS). Recommendation: effectiveness not established 
 
Gomes-
Villas et al., 
2012 
Descriptive 
single 
site/ 
Brazil 
162 
type 2 diabetes under 
outpatient follow-up with 
insulin, oral anti-diabetic 
and/or associated meds 
 
avg age=59.4 years 
 
M=42%, F=58% 
Direct but weak correlations were observed 
between SS and non-med treatment adherence 
(r=0.21, p=0.01) as well as between SS and 
med treatment adherence (r=0.18, p=0.02)  
limited time 
period of study, 
self-report 
 Kunustor et al., 2011 RCT 
single/ 
Uganda 174 
currently receiving ART 
 
mean age=39.1 years 
 
M=32%, F=68% 
Mean adherence was 99.1% (95%CI:98.3%-
99.9%) for the TS arm and 96.3% (95%CT: 
94.2%-98.3%) for the non-TS arm. The diff 
was non signif (P>0.05) 
showed no 
difference but 
author 
says was 
underpowered, 
culture 
Intervention: HCP Support. Recommendation: effectiveness not established 
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Table B2 
 
Evidence Table for Recommendations on Intervention Categories to Improve Adherence 
 Author Study Design Site info N Sample Findings Limitations 
 Farmer et al., 2012 RCT 
multi/ 
UK 211 
type 2 diabetes of at least 3 
months duration, currently 
taking oral GLM and with 
HBA >7.5% 
 
median age=63.2 years 
 
M=65.4%, F=34.6% 
IG group=77.4% mean adherent days vs 69% 
in CG;mean difference between groups in 
percentage of days that the correct number of 
doses of med was taken as prescribed was 
8.4% (95% CI 0.2%-16.7%, p=0.0444);  
risk of bias-
attentional 
control & no 
blinding, self-
report 
 Holzemer et al., 2000 descriptive 
single/ 
US 10 
receiving home care 
services for HIV/AIDS 
 
avg age=42.6 years 
 
M-n=7, F-n=3 
Patients have knowledge and skill deficits 
related to adherence (frequency=50%, 
dose=50%, side effects=10%) and 
management of s/e (thirst=60%, sweats=50%, 
gas=30%, lightheadedness=30%, dry 
mouth=20%, aches=20%) 
small sample, no 
control or 
random 
assignment, self-
report 
 Lee et al., 2006 RCT 
single/ 
US 174 
taking 4 chronic 
medications 
 
mean age=78 years 
 
M=77.1 %, F=12.9% 
After 6 months of the intervention, medication 
adherence increased to 96.9% (p<0.001) and 
was associated with significant improvements 
in systolic BP (reduced from 133.2 to 129.9 
mm Hg; p=0.02) and LCL-C (decreased from 
91.7 to 86.8 mg/dl; p=0.001); six months after 
randomization, the persistence of med 
adherence decreased to 69.1% in usual care 
arm, where it was sustained at 95.5% in 
pharmacy care (p<0.001). 
no random 
assignment, 
elderly, at 
military hosp so 
cost not issue 
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Table B2 
 
Evidence Table for Recommendations on Intervention Categories to Improve Adherence 
 Author Study Design Site info N Sample Findings Limitations 
 Sherman et al., 2009 
Retrospective non-
case controlled 
multi/ 
US 17,610 
patients with at least 1 
prescription for 1 or more 
drugs within the 20 
therapeutic classes 
identified 
 
mean age=60.39 years 
 
M=55.72%, F=44.28% 
Across the 20 therapeutic classes the 
workplace treated patients had overall 
adherence rates 9.72% higher than those of 
community treated patients. The pattern was 
repeated with an overall adherence rate that 
was 9.52% higher for workplace treated 
patients when prescriptions were limited to 
medication new starts. Workplace treated 
group was 26.7% more likely to have an 80% 
or higher adherence rate (p<0.0001). 
pharmacy on site 
 Sommers et al, 2012 
prospective 
observational 
feasibility 
single/ 
US 24 
gastrointestinal cancer 
prescribed at least one oral 
chemotherapy agent 
 
mean age=53 years 
 
M-n=23, F-n=7 (gender 
provided for initial n of 
30) 
23/24 participants were able to verbalize 
knowledge of drug name, purpose, admin 
schedule and what to do in case of 
missed/skipped doses. All 24 reported using a 
method of tracking administration, including 
themed diary, an alarm and reminders. 21/24 
were able to identify 1-3 side effects of their 
med but could not always identify the most 
common side effect.   MMAS-8 scores ranged 
from 5-8 (x=7.89, SD=0.55) with higher scores 
indicating higher adherence. 
short duration of 
study, 
Hawthorne 
effect, sm 
sample, no 
attentional 
control, no 
blinding 
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Table B2 
 
Evidence Table for Recommendations on Intervention Categories to Improve Adherence 
 Author Study Design Site info N Sample Findings Limitations 
 Williams et al., 2012 RCT 
single/ 
Austra-
lia 
75 
patients with diabetes, 
chronic kidney disease and 
systolic hypertension 
 
mean age-68 years int arm, 
66 years cont arm 
 
M=56.4&, F=43.6% 
Mean adherence rate to meds was 22.2% in 
control group and 24.3% in intervention group 
(p=0.162); no stat diff 
small sample, not 
generalizable 
 Wu et al., 2006 RCT 
Single/ 
Hong 
Kong 
442 
5 or more drugs on at least 
2 consecutive visits to 
clinic 
 
Mean age=71.2 years in 
int group, 70.5 in control 
group 
 
M=49% int group, 48% 
control group, F=51% in 
int group, 52% in control 
group 
Fewer patients who were non-compliant at 
enrollment remained non-compliant at end of 
study in intervention group than in control 
group (7% v 18%, p<0.001). More patients 
who turned compliant at enrollment remained 
compliant in the intervention group than in the 
control group (81% v 58%, p=0.038). 
no blinding, no 
attentional 
control,  
self-report, single 
site, >10% w/d 
but d/t deaths 
Intervention: Technology. Recommendation: likely to be effective 
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Table B2 
 
Evidence Table for Recommendations on Intervention Categories to Improve Adherence 
 Author Study Design Site info N Sample Findings Limitations 
 Fisher et al., 2011 RCT 
multi/ 
US 328 
prescribed ART 
(antiretroviral therapy) 
 
mean age=47% 
 
gender not stated 
For ITT, an increasing proportion of 
participants in the intervention arm reporting 
perfect adherence on ACTG 3 day adherence 
measure (p=0.12) and on the VAS 3-4 week 
adherence measure (p=0.12) as time 
progressed from baseline did not reach 
statistical significance. 
high withdrawal, 
requires 
hardware 
& software 
 Kalichman, et al., 2011 RCT 
single/ 
US 40 
receiving ART 
 
mean age=51 years 
 
M-n=26, F-n=14 
adherence improved from 87% of pills taken at 
baseline to 94% adherence 4 months after 
baseline (p<0.01). Effect sizes ranged from 
moderate (d=0.45) to large (d=0.80). Gains in 
adherence were paralleled with increased self-
efficacy (p<0.05) and use of behavioral 
strategies for ART adherence (p<0.05).   
small sample, 
convenience 
sample 
  
 Piette et al., 2000 RCT 
multi/ 
US 280 
diabetes >6 months and 
using hypoglycemic 
medication 
 
mean age=55 years 
 
M=41%, F=59% 
Automated telephone assessment and self care 
education calls with nurse follow up increased 
adherence to medications (48% vs 69%, 
p=0.003) 
unblinded, self-
report 
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Table B2 
 
Evidence Table for Recommendations on Intervention Categories to Improve Adherence 
 Author Study Design Site info N Sample Findings Limitations 
 Lawrence et al., 2008 RCT 
multi/ 
US 155 
participating in disease 
management programs for 
CVD or diabetes 
 
age range=18-65 years 
 
M=51.1 years int group, 
42.6 in control group, 
F=47.9 years in int group, 
57.4 in control group 
In 17 months of program experience, 199 late 
med refills among a 155 patients and controls, 
in the intervention group, 123 late meds for 94 
patients, in control group, 76 late meds in 61 
patients. Intervention group had a significantly 
higher rate of med reinitiation (59.3) than the 
control group (42.1) (P<0.05). Time to 
reinitiation was significantly shorter in the 
intervention group 59.5 days vs 107.4 days for 
control group. 
no blinding, short 
study period,  
pts self-selected 
to participate 
 Reidel et al., 2008 feasibility 
multi/ 
Canada 99 
patients enrolled in 
electronic prescribing and 
medication management 
who were taking chronic 
disease related drugs in the 
3 months prior to start of 
study 
 
age=60->80 years, 
45.5%=70-79 years 
 
M=47.4%, F=52.6% 
The majority found IVR system’s voice 
acceptable and did not have problems setting 
up the time and location of reminder calls. 
Many experienced technical problems when 
called for reminders, such as incorrect time of 
calls and voice recognition difficulties. Most 
participants had already refilled their 
prescriptions when they received the reminder 
calls, reporting they did not have difficulties 
remembering to refill prescriptions on their 
own.  
self-selected 
group, study 
terminated 
early d/t 
technical flaws 
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Table B2 
 
Evidence Table for Recommendations on Intervention Categories to Improve Adherence 
 Author Study Design Site info N Sample Findings Limitations 
 Spoelstra et al, 2013 RCT 
multi/ 
US 91 
solid tumor cancer dx and 
being on nonhormonal oral 
agents 
 
mean age=59.6 years 
 
M=30%, F=70% 
Q1-comparisons on adherence rates: 42% 
were nonadherent, for those who completed all 
8 AVR calls adherence rate increased 9% 
(p=0.11) in the AVR + nurse for sx and adh 
strategies, AVR + nurse for adh only increased 
by 3% (p=0.54) and declined by 4% (p=0.36) 
in the AVR plus SMT only.   
small sample, 
>10% w/d, self-
report 
      
Q2-comparisons on symptom severity: 
Group 1 mean scored decreased 4.74, p=0.03, 
group 2 mean score decreased 6.76, p=0.04 
and group 3 had no significant decrease in 
symptom severity, mean scored decreased 
2.16, p=0.39.  
 
      
Q3-comparison on adherence and symptom 
severity-multivariate analysis showed no 
signif differences between groups in symptom 
severity at baseline and at end of study. 
Symptom severity declined in all and there 
were no signif differences between groups. 
Type of intervention did not make a difference 
in symptom severity. 
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Appendix C: ONS Putting Evidence into Practice Weight of 
Evidence Classification Schema1 
S.A. Mitchell, MScN, CRNP, AOCN® and C.R. Friese, PhD, MS, RN, 
AOCN® 
On behalf of the ONS Oncology Nursing Interventions for Patient Outcomes Project 
Team 
 
Background 
 
The classification schema outlined below was developed to assist in evaluating a 
collective body of evidence about a health intervention for the purpose of informing 
decisions on implementation. Based on the work of Ciliska, Cullum and Marks 
(2001), Hadorn, Baker, Hodges and Hicks (1996), Rutledge, DePalma, & 
Cunningham (2004), and Ropka and Spencer-Cisak (2001), the schema was intended 
for application to bodies of existing research-based knowledge on health 
interventions for patients with cancer. The schema itself does not seek to guide the 
decision process in relation to an intervention for an individual patient. Such 
decisions should be made within the interdisciplinary team, and based on individual 
patient characteristics, values, and preferences, a consideration of potential harms as 
well as benefits, and an assessment of the feasibility of implementing the intervention 
within the specific care setting. 
 
A schema developed for appraising evaluative research should not be used to remove 
interventions from further consideration because of inadequate evidence about 
intervention effectiveness. Criterion-based evaluation of evidence is valid only where 
a significant body of high quality evidence is available. It is critical to avoid 
interpreting insufficient evidence on the one hand, or poor-quality evidence on the 
other, as meaning that an intervention is unimportant or ineffective. Insufficient 
evidence or a lack of evidence simply means that evaluative research of an 
intervention has not been done at the level necessary to make conclusions with 
confidence that an intervention produces a specific outcome/patient benefit. The lack 
of evidence on an intervention, or the availability only of poor-quality evidence, may 
indicate a gap in knowledge and a need for additional research. The schema can 
therefore also be used to highlight research gaps, and to identify the types of research 
that could address those gaps. 
 
Panels of advanced practice nurses, staff nurses, and doctorally-prepared nurse 
researchers reviewed the literature base in the identified outcome areas. Professional 
                                                 
1 Note. From ONS PEP (Putting Evidence Into Practice) Weight of Evidence Classification Schema: 
Decision Rules for Summative Evaluation of a Body of Evidence. Retrieved from 
http://www.ons.org/research/media/ons/docs/research/outcomes/weight-of-evidence-table.pdf. Copyright 
by Oncology Nursing Society. Reprinted with permission. 
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ONS PUTTING EVIDENCE INTO PRACTICE 
ONS PEP (Putting Evidence into Practice) WEIGHT OF EVIDENCE 
CLASSIFICATION SCHEMA 
Decision Rules for Summative Evaluation of a Body of Evidence 
 
 
health services librarians assisted in the conduct of the literature searches. Based on 
their analysis, the panels then formulated a judgment about the body of evidence 
related to the intervention under consideration. Three major components were 
considered by the panels in classifying the collective evidence into one of six Weight 
of Evidence categories: 
 
•  Quality of the data, with more weight assigned to levels of evidence higher in the 
PRISM categorization (such as randomized trials, and meta-analyses) 
• Magnitude of the outcome (eg. effect size or minimal clinically important 
difference) 
• Concurrence among the evidence (based on the premise that an investigator 
has less confidence in findings in which the lines of evidence contradict one 
another) 
 
Recommended for Practice 
Interventions for which effectiveness has been demonstrated by strong evidence from 
rigorously-designed studies, meta-analyses, or systematic reviews, and for which 
expectation of harms is small compared with the benefits. 
 
• Supportive evidence from at least two well-conducted randomized controlled 
trials that were performed at more than one institutional site, and that included a 
sample size of at least 100 participants 
 
• Evidence from a meta-analysis or systematic review of research studies that 
incorporated quality ratings in the analysis, and included a total of 100 patients 
or more in its estimate of effect size and confidence intervals 
 
 
• Recommendations from a panel of experts, that derive from an explicit literature 
search strategy, and include thorough analysis, quality rating, and synthesis of 
the evidence 
 
Likely to Be Effective 
Interventions for which the evidence is less well established than for those listed under 
‘recommended for practice’’. 
 
• Supportive evidence from a single well conducted randomized controlled trial 
that included fewer than 100 patients or was conducted at one or more 
institutions 
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ONS PEP (Putting Evidence into Practice) WEIGHT OF EVIDENCE 
CLASSIFICATION SCHEMA 
Decision Rules for Summative Evaluation of a Body of Evidence 
 
 
 
• Evidence from a meta-analysis or systematic review that incorporated quality ratings 
in the analysis and included fewer than 100 patients, or had no estimates of effect 
size and confidence intervals 
 
• Evidence from a synthetic review of randomized trials that incorporated 
quality ratings in the analysis 
 
• Guidelines developed largely by consensus/expert opinion rather than primarily 
based on the evidence and published by a panel of experts, that are not supported 
by synthesis and quality rating of the evidence 
 
Benefits Balanced with Harms 
Interventions for which clinicians and patients should weigh up the beneficial 
and harmful effects according to individual circumstances and priorities. 
 • Supportive evidence from one or more randomized trials, meta-analyses or 
systematic reviews, but where the intervention may be associated, in certain patient 
populations, with adverse effects that produce or potentially produce mortality, 
significant morbidity, functional disability, hospitalization or excess length of stay 
 
Effectiveness Not Established 
Interventions for which there are currently insufficient data or data of inadequate 
quality. 
 
• Supportive evidence from a well conducted case control study 
 
• Supportive evidence from a poorly controlled or uncontrolled study 
 
• Evidence from randomized clinical trials with one or more major or three or    more 
minor methodological flaws that could invalidate the results 
 
• Evidence from non-experimental studies with high potential for bias (such as  case 
series with comparison to historical controls)-Evidence from case series  or case 
reports 
 
• Conflicting evidence, but where the preponderance of the evidence is in support of 
the recommendation or meta-analysis showing a trend that did not reach statistical 
significance 
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Effectiveness Unlikely 
Interventions for which lack of effectiveness is less well established than for those 
listed under ‘not recommended for practice’. 
 
• Evidence from a single well conducted randomized trial with at least 100 
participants or conducted at more than one site and which showed no benefit for the 
intervention 
 
• Evidence from a well conducted case control study, a poorly controlled or 
uncontrolled study, a randomized trial with major methodologic flaws, or an 
observational study (eg. case series with historical controls) that showed no benefit 
and a prominent and unacceptable pattern of adverse events and serious toxicities 
(CTCAE Grade III/IV) 
 
 
Not Recommended for Practice 
Interventions for which ineffectiveness or harmfulness has been demonstrated by 
clear evidence, or the cost or burden necessary for the intervention exceeds 
anticipated benefit 
• Evidence from two or more well conducted randomized trials with at least 100 
participants or conducted at more than one site and which showed no benefit for the 
intervention, and excessive costs or burden expected 
 
• Evidence from a single well conducted trial that showed a prominent and 
unacceptable pattern of adverse events and serious toxicities (CTCAE Grade 
III/IV) 
 
• Evidence from a meta-analysis or systematic review of research studies that 
incorporated quality ratings in the analysis, included a total of 100 patients or 
more in its estimate of effect size and confidence intervals with demonstrated lack 
of benefit or prominent and unacceptable toxicities 
 
• Intervention discouraged from use by a panel of experts in the related subject, after 
conducting a systematic examination, quality rating and synthesis of the available 
evidence 
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